 
I5Q-MC -CGAH (a) Clinical Protocol 
 
 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with 
Episodic Migraine – the EVOLVE -2 Study 
 
 [STUDY_ID_REMOVED]  
 
Approval Date: 22-Jan-2016 
 
 
I5Q-MC-CGAH (a)Clinical Protocol Page 1
LY2951742 Approved: 22 January 2016Protocol I5Q-MC-CGA H(a)
A Phase 3, Randomized, Double -Blind, Placebo -Controlled 
Study  of LY2951742 in Patients with Episodic Migraine
–the EVOLVE -2 Study
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.   It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the cli nical investigation of 
LY2951742 , unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries.
Note to Regulatory Authorities :  this document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure .  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release .  In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 a nd may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
LY2951742
Study CGAH is a Phase 3, multisite, randomized, double -blind, placebo -controlled, 6 -month 
study to compare the efficacy and safety of two doses of LY2951742 with placebo in 
preventing migraine headaches in patients with episodic migraine (with or without aura).
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol Electronically Signed and Approved by Lilly :  23 Se ptember 2015
Protocol Amendment (a) Electronically Signed and Approved by Lilly on approval date 
provided below.
Approval Date: 22-Jan-2016 GMT
I5Q-MC-CGAH (a)Clinical Protocol Page 2
LY2951742 Approved: 22 January 2016Table of Contents
Section Page
1. Protocol  Synopsi s................................................................................................................ 8
2. Introduction ...................................................................................................................... 11
2.1. Background .................................................................................................................. 11
2.2. Study  Rati onale ............................................................................................................ 11
3. Object ives and Endpo ints.................................................................................................. 13
4. Study  Design ................................................................
..................................................... 19
4.1. Overview of Study  Design ........................................................................................... 19
4.2. End of Trial Definit ion.................................................................................................21
4.3. Scientific Rationale for Study  Design ........................................................................... 21
4.4. Justification for Dose ................................................................................................... 21
4.5. Benefit/Risk Assessment .............................................................................................. 21
5. Study  Popul ation............................................................................................................... 22
5.1. Inclusio n Cri teria.......................................................................................................... 22
5.2. Exclusio n Cri teria........................................................................................................ 23
5.3. Screen Failures ............................................................................................................. 26
5.4. Lifest yle and/or Dietary Requirements ......................................................................... 26
6. Treatment .......................................................................................................................... 27
6.1. Treatments Administered ............................................................................................. 27
6.1.1. Medical Devices ................................................................................................... 27
6.2. Method of Treatm ent Assignment ................................................................................ 27
6.2.1. Selection and Timing o f Doses ............................................................................. 27
6.3. Blinding ....................................................................................................................... 27
6.4. Packaging and Labelling .............................................................................................. 28
6.5. Preparati on/Handling/Storage ....................................................................................... 28
6.6. Dose Modificat ion........................................................................................................ 28
6.6.1. Speci al Treatm ent Consi derat ions........................................................................ 28
6.7. Treatment Compliance .................................................................................................28
6.8. Concomitant Therapy ................................................................................................... 29
6.9. Treatment after Study  Com pletion................................................................................ 30
6.9.1. Study  Extensio ns.................................................................................................. 30
6.9.2. Continued Access .................................................................................................30
7. Discontinuati on Cri teria .................................................................................................... 31
7.1. Discontinuati on from Study  Treatm ent......................................................................... 31
7.1.1. Perm anent Discont inuat ion from Study Treatment ............................................... 31
I5Q-MC-CGAH (a)Clinical Protocol Page 3
LY2951742 Approved: 22 January 20167.1.2. Temporary  Discont inuat ion from Study  Treatm ent............................................... 31
7.1.3. Discontinuati on of  Inadvertent ly Enrolled Patients ............................................... 31
7.1.4. Perm anent Discont inuat ion from the Study .......................................................... 32
7.1.5. Patients Lost to Follow -Up................................................................................... 32
8. Study  Assessments and Procedures ................................................................................... 33
8.1. Efficacy Assessments ................................................................................................... 33
8.1.1. Primary Efficacy  Assessments ............................................................................. 33
8.1.2. Secondary  Efficacy  Assessments .......................................................................... 33
8.1.2.1. Patient Gl obal Impressi on of Severi ty............................................................. 33
8.1.2.2. Patient Gl obal Impressi on of Improvement ..................................................... 33
8.1.3. Appropriateness of Assessments .......................................................................... 33
8.2. Adverse Events ............................................................................................................ 34
8.2.1. Serious Adverse Events ........................................................................................ 34
8.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 35
8.2.1.2. Adverse Event Monitoring with a Systemat ic 
Quest ionnaire .................................................................................................35
8.2.2. Com plaint Handling ............................................................................................. 36
8.3. Treatment of Overdose .................................................................................................36
8.4. Safety Assessments ...................................................................................................... 36
8.4.1. Electrocardiograms .............................................................................................. 36
8.4.2. Vital Signs ........................................................................................................... 36
8.4.3. Laboratory  Tests .................................................................................................. 36
8.4.4. Other Tests ........................................................................................................... 37
8.4.5. Safety Moni toring ................................................................................................ 37
8.5. Pharmacokinet ics......................................................................................................... 37
8.6. Pharmacodynamics ...................................................................................................... 38
8.8. Biomarker s................................................................................................................... 39
8.8.1. Samples for Immunogenicit y Research .................................................................39
8.9. Heal th Economics ........................................................................................................ 39
9. Statistical Considerations and Data Analysis ..................................................................... 41
9.1. Determinat ion of Sample Size ...................................................................................... 41
9.2. General Statist ical Considerat ions................................................................................ 41
9.3. Treatment Group Comparabilit y................................................................................... 42
9.3.1. Patient Disposi tion............................................................................................... 42
9.3.2. Patient Characteri stics.......................................................................................... 42
9.3.3. Concomitant Therapy ........................................................................................... 42
9.3.4. Treatment Compliance ......................................................................................... 42
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 4
LY2951742 Approved: 22 January 20169.3.5. Electronic Pat ient-reported Outcome Diary Co mpliance ....................................... 43
9.4. Primary and Secondary  Analyses ................................................................................. 43
9.4.1. Primary Analyses .................................................................................................43
9.4.2. Key Secondary  Analyses ...................................................................................... 44
9.4.3. Other Secondary  and Terti ary Efficacy Analyses .................................................. 45
9.5. Safety Analyses ............................................................................................................ 46
9.5.1. C ategori cal Safety  Vari ables ................................................................................ 46
9.5.2. Adverse Events .................................................................................................... 46
9.5.3. Suicide-Related Thoughts and Behaviors ............................................................. 47
9.5.4. Vital Signs and Weight ........................................................................................ 47
9.5.5. Electrocardiogram Intervals and Heart Rate ......................................................... 47
9.5.6. Laboratory  Tests .................................................................................................. 48
9.7. Other Analyses ............................................................................................................. 48
9.7.1. Health Economics ................................................................................................ 48
9.7.2. Subgroup Analyses .............................................................................................. 48
9.8. Interim Analyses .......................................................................................................... 49
10. Study Governance Considerat ions..................................................................................... 51
10.1. Regulatory  and Ethi cal Considerat ions, Including the Informed 
Consent Process ........................................................................................................... 51
10.1.1. Inform ed Consent .................................................................................................51
10.1.2. Ethical Review ..................................................................................................... 51
10.1.3. Regulatory  Considerat ions................................................................................... 51
10.1.4. Invest igator Informat ion....................................................................................... 52
10.1.5. Protocol  Signatures .............................................................................................. 52
10.1.6. Final Report Signature ......................................................................................... 52
10.2. Data Qualit y Assurance ................................................................................................ 52
10.2.1. Data Capture System ............................................................................................ 53
10.3. Study  and Si te Cl osure .................................................................................................54
10.3.1. Discontinuati on of  Study  Sites............................................................................. 54
10.3.2. Discontinuati on of  the Study ................................................................................ 54
11. References ........................................................................................................................ 55
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 5
LY2951742 Approved: 22 January 2016List of Tables
Table Page
Table CGAH.1. Object ives and Endpo ints............................................................................... 13
Table CGAH.2. Migraine and Headache Endpo int Definit ions................................................ 18
Table CGAH.3. Treatments Allowed and Treatments Not Allowed as Conco mitant 
Therapy ......................................................................................................... 29
Table CGAH.4. Definit ion of Subgroup Variables .................................................................. 49
I5Q-MC-CGAH (a)Clinical Protocol Page 6
LY2951742 Approved: 22 January 2016List of Figures
Figure Page
Figure CGAH.1. Illustrati on of  study  design for Clinical Protocol I5Q -MC-CGAH. ................. 19
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 7
LY2951742 Approved: 22 January 2016List of A ppendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 57
Appendix 2. Schedule of Act ivities.................................................................................... 58
Appendix 3. Clinical Laboratory  Tests ............................................................................... 63
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................... 65
Appendix 5. Protocol  Amendment I5Q -MC-CGAH(a) Summary:  A Phase 3, 
Randomized, Double -Blind, Pl acebo -Controlled Study  of LY2951742 
in Patients with Episodic Mi graine –the EVOLVE -2 Study ........................... 66
I5Q-MC-CGAH (a)Clinical Protocol Page 8
LY2951742 Approved: 22 January 20161.Protocol Synopsis
Title of Study:
A Phase 3, Randomized, Double -Blind, Placebo -Controlled Study of LY2951742 in Patients with Episodic Migraine
–the EVOLVE -2 Study .
Rationale :
Study I5Q-MC -CGA H(CGAH ; EVOLVE -2) is intended to assess the efficacy and safety of two doses of
LY2951742 in the prevention of migraine headache compared with placebo in patient s suffering from episodic 
migraine.   Episodic migraine is defined as 4 to 14 migraine headache days (with or without aura) per month.
Objective(s)/Endpoints:
Objectives Endpoints
Primary
To test the hypothesis that at least 1 dose of LY2951742 
(120 o r 240 mg/month) is superior to placebo in the 
prevention of migraine headache in patients with 
episodic migraine.The overall m ean change from baseline in the number 
of monthly migraine headache days during the 6 -
month double -blind treatment phase
Key Secondary Objectives
If LY2951742 (120 or 240 mg/month ) is statistically 
significantly  superior to placebo on the primary 
objective , the following key secondary objectives will be 
tested w ith adjustment for multiplicity (only the key 
secondary objectives a re listed below):The specific methodology (including testing order, 
relatio nship and type I error allocation and 
propagation) for the tests of the following key 
secondary endpoints will be specified in t he statistical 
analy sis plan:
To compare LY295174 2 with placebo with respect 
to50% response rateThe proportion of patients with reduction from 
baseline ≥50% in monthly  migraine headache 
days during the 6- month double -blind treatment 
phase
To compare LY2951742 with placebo with respect 
to 75% response rateThe proportion of patients with reduction from 
baseline ≥75% in monthly migraine headache 
days during the 6- month double -blind treatment 
phase
To compare LY2951742 with placebo with respect 
to 100% response rateThe proportion of patients with a 100% reduction 
from baseline in monthly migraine headache 
days during the 6- month double -blind treatment 
phase 
I5Q-MC-CGAH (a)Clinical Protocol Page 9
LY2951742 Approved: 22 January 2016Objectives Endpoints
To compare LY2951742 with placebo with respect 
tochange in function ingThe mean change from baseline in the Role 
Function -Restrictive domain score of the 
Migraine -Specific Quality of Life Questionnaire 
version 2.1 (MSQ v2.1) (average of Months 4, 5,
and 6)
To compare LY2951742 with placebo with respect 
to change i n use o f acute (abortive )migraine 
treatmentThe overall m ean change from baseline in the 
number of monthly migraine headache days 
requiring medication for the acute treatment of 
migraine or headache during the 6 -month double -
blind treatment phase
To compare LY2 951742 with placebo with respect 
to change in global severity of the migraine 
conditio nThe mean change from baseline in the Patient 
Global Impression of Severity (PGI -S) score 
(average of Months 4, 5, and 6)
Summary of Study Design :
A multisite , randomized, double -blind, parallel, placebo -controlled trial with 4 study periods in patients who meet 
International Classification of Headache Disorders ( ICHD )criteria for a diagnosis of migraine as confirmed during a 
prospective baseline period thatdemonstrate sepisodic frequency (4 to 14 migraine headache days per month) .
Treatment Arms and Duration:
Three treatment arms :  LY2951742 (120 mg/month with a 240 mg loading dose at the first injection [administered 
as 2 injections of 120 mg at Visit 3]), L Y2951742 (240 mg/month, administered as 2 injections of 120 mg), and 
placebo.   Following a prospective baseline (30 -
40 days) period, eligible patients will be randomized in a 2:1:1 ratio 
to receive placebo, 120 mg/month of LY2951742, or 240 mg/month of LY2 951742, respectively, and will begin a 6 -
month treatment phase.  This phase will be followed by a 4 -month, post -treatment phase during which patients will 
no lo nger receive any study medication.
Number of Patients :
The study  will screen an estimated 1557 p otential study participants to ensure randomization of approximately 825 
patients with episodic migraine .
Statistical Analysis:
Unless otherwise specified , analy ses will be conducted on an intent -to-treat (ITT) population, which include all 
patients who are randomized and receive at least one dose of investigational product . Patients in the ITT population 
will be analyzed according to the treatment group t o which they are randomized .  When  mean change from baseline 
is assessed, the patient will be included in the analysis only if the patient has a baseline and postbaseline 
measurement.
The primary analysis will evaluate the efficacy of two doses of LY295174 2 compared with placebo on the overall 
mean change from baseline in the number of monthly migraine headache days during the 6- month double -blind 
treatment phase. Migraine headache day will be defined to include both migraine and probable migraine days .  The 
I5Q-MC-CGAH (a)Clinical Protocol Page 10
LY2951742 Approved: 22 January 2016primary  analy sis will be performed using a restricted maximum likelihood based mixed models repeated measures 
(MMRM) technique.  The analysis will include the fixed categorical effects of treatment, regio n, month, and 
treatment -by-month interaction, as well as the continuous fixed covariates of baseline number of migraine headache 
days and baseline number of migraine heada che days -by-visit interaction .
I5Q-MC-CGAH (a)Clinical Protocol Page 11
LY2951742 Approved: 22 January 20162.Introduction
2.1. Background
Migraine is a chronic, debilitat ing condit ion found to be one of the top 10causes of disabilit y 
expressed as years lived with disabilit y globally (Vos et al . 2012).  However, one study  estimates 
that only a small fract ion of patients receive prevent ive treatment, although more than 25% of 
migraineurs are in need of prevent ive therap y (Rizzoli  2014).  Despite the availabilit y of 
prevent ive medicat ions for migraine, significant needs remain for new treatm ent opti ons wi th 
improved efficacy and tolerabilit y.
Calcitonin gene -related pepti de(CGRP), a 37 -amino acid neuropeptide , is widely expressed 
throughout the central and peripheral nervous sy stem and acts as a local facilitator of 
inflammatory  processes .  CGRP is implicated in the pathophysio logy of migraine and is 
hypothesized to be invo lved in the release o f inflammatory mediators and the transmissio n of
nociceptive (pain) informat ion from intracranial  blood vessels to the nervous system (Villal ón
and Olesen 2009). In migraineurs, serum concentrations o f CGRP are significant ly elevated 
during migraine attacks (Goadsby et al. 1990; Goa dsby and Edvinsson 1993) ,and infusio n of 
CGRP to individuals wit h a history  of migraine can trigger migraine attacks (Lassen et al. 1998 ;
Lassen et al. 2002). The n eutraliz ation of CGRP with antibodi es has been shown to modulate 
neurogenic inflammat ion; thus, these ant ibodies may represent a promising pharmaco logic
approach for the prevent ion of migraine (Investi gator’s Brochure [IB], Section 3.1) .
LY2951742 is a humanized monoclonal ant ibody  that potently  and selectively binds t o CGRP, 
prevent ing CGRP -mediated bi ological effects (IB, Section 3.1).  To date, m ore than 450 clinical 
trial parti cipants have been exposed to LY2951742 at single doses ranging fro m 1 to 600 mg and 
multiple doses up to 300 mg in 5 clinical trials of LY2951742.  In studies of pat ients with 
migraine ( Studi es I5Q -MC-ART1 [ART -01] and I5Q -MC-CGAB [CGAB]), efficacy data have 
demonstrated that LY2951742 had significant ly greater mean reduction s than placebo in 
migraine headache days and other efficacy  parameters.  Across clinical studies of LY2951742, 
assessment of adverse events (AEs) indicates that LY2951742 has been well tolerated in both 
healt hy subjects and in pat ients with episodi c migraine.  The AEs generally  have been mild to
moderate in severit y. In two studies of pat ients with migraine, the most frequent ly reported 
adverse events (AEs) included inject ion-site pain, upper respi ratory  tract infection, abdominal 
pain, di zziness, inject ion
-site ery thema, rash, hypertension, and nasopharyngit is.  Analyses of 
laboratory  values and cardio vascular monitoring of the clinical studies have shown no other 
clinically important changes in tested parameters .
2.2. Study Rationale
Study  I5Q-MC-CGAH (EVOLVE -2) will enable a more comprehensive clin ical assessment of 
LY2951742 in a patient populat ion for whi ch the drug already has shown preliminary evidence 
of efficacy and safet y.  Thi s study , along wi th a study  of identical design in pat ients with 
episodic migraine, is intended to provide pivotal ef ficacy data to support a registration program 
in patients with migraines.  EVOLVE -2 will include 6 months on LY2951742 or pl acebo
I5Q-MC-CGAH (a)Clinical Protocol Page 12
LY2951742 Approved: 22 January 2016followed by 4 m onths of post -treatm ent observat ionto deepen understanding of the effects of a 
CGRP ant ibody  in prevent ing migraines .
I5Q-MC-CGAH (a)Clinical Protocol Page 13
LY2951742 Approved: 22 January 20163.Objectives and Endpoints
Table CGA H.1shows the key  object ives and endpo ints ofthe study .  Table CGA H.2provi des 
definit ions for the terms referenced below.
Table CGAH.1. Objectives and Endpoints
Objectives Endpoints
Primary
To test the hypothesis that at least 1 dose of LY2951742 
(120 o r 240 mg/month) is superior to placebo in the 
prevention of migraine headache in patients with 
episodic migraine.The overall mean change from baseline in the number of 
monthly migraine headache days during the 6-mo nth 
double -blind tre atment phase
Key Secondary Objectives
If LY2951742 (120 or 240 mg/month ) is statistically 
significantly  superior to placebo on the primary 
objective , the following key secondary objectives will be 
tested w ith adjustment for multiplicity:The specific met hodology (including testing order, 
relatio nship and type I error allocation and propagation) 
for the tests of the following key secondary  endpoints
will be specified in t he statistical analysis plan:
To compare LY2951742 with placebo with respect 
to 50% response rateThe proportion of patients with reduction from 
baseline ≥50% in monthly migraine headache days 
during the 6 -month double -blind treatment phase
To compare LY2951742 with placebo with respect 
to 75% response rateThe proportion of patients wit h reduction from 
baseline ≥75% in monthly migraine headache days 
during the 6 -month double -
blind treatment phase
To compare LY2951742 with placebo with respect 
to 100% response rateThe proportion of patients with a 100% reduction 
from baseline in monthly migraine headache days 
during the 6 -month double -
blind treatment phase
To compare LY2951742 with placebo with respect 
to change in function ingThe mean change from baseline in the Role
Function -Restrictive domain score of the Migraine -
Specific Quality of Life Questionnaire version 2.1 
(MSQ v2.1) (average of Months 4, 5,and 6)
I5Q-MC-CGAH (a)Clinical Protocol Page 14
LY2951742 Approved: 22 January 2016Table CGAH. 1. Objectives and Endpoints (continued)
Objectives (cont.) Endpoints (cont.)
Key Secondary Objectives (cont.)
To compare LY2951742 with placebo with respect 
to change in use of acute (abortive) migraine 
treatmentThe overall mean change from baseline in the 
number of monthly migraine headache days 
requiring medication for the acute treatment of 
migraine or headache during the 6 -month double -
blind treatment phase
To compare LY2951742 with placebo with respect 
to change in global severity of migraine conditionThe mean change from baseline in the Patient 
Global Impression of Severity (PGI -S) score 
(average of Months 4, 5, and6)
Other Secondary Objectives
To compare LY2951742 with placebo with respect 
to change in headache daysThe overall m ean change from baseline in the 
number of monthly headache days during the 6 -
month double -blind treatment phase
To compare LY2951742 with placebo with respect 
to change in moderate to severe headache daysThe overall m ean change from baseline in the 
number of monthly moderate to severe headache 
days during the 6- month double -blind treatment 
phase
To compare LY2951 742 with placebo with respect 
to a 30% response rateThe proportion of patients with reduction from 
baseline ≥30% in monthly migraine headache days 
during the 6 -month double -blind treatment phase
To compare LY2951742 with placebo with respect 
to distribution of response ratesCumulative d istribution of monthly migraine 
headache day response rates during the 6-mo nth 
double -blind treatment phase
To compare LY2951742 with placebo with respect 
to time to 50% responseTime to first occurrence of a ≥50% reduction from 
baseline in the number of monthly migraine 
headache days (Kaplan -Meier analysis)
To compare LY2951742 with placebo with respect 
to onset of effectTheinitial month at which statistical separation in 
mean change from baseline in the number of 
monthly migraine headache days is demonstrated
and maintained at all subsequent months through 
Month 6
To compare LY2951742 with placebo with respect 
to onset of 50% sustained responseThe initial month at which s tatistical separation in 
the propor tion of patients meeting at least a 50% 
reductio n in monthly migraine headache days that is 
maintained at all subsequent months through Month 
6
I5Q-MC-CGAH (a)Clinical Protocol Page 15
LY2951742 Approved: 22 January 2016Table CGAH. 1. Objectives and Endpoints (continued)
Objectives (cont.) Endpoints (cont.)
Other Secondary Objectives (cont.)
To compare LY2951742 with placebo with respect 
to maintenance of 50% responseThe proportion of patients who maintain 50% 
response criteria for at least 3 consecutive months to 
the end of the double -blind treatment phase and the 
proportion of patients who maintain 50% response 
criteria for 6 consecutive months during double -
blind treatment
To compare LY2951742 with placebo with respect 
to changes in other efficacy parameters, 
specifically:
oInternational Classification of Headache 
Disorders (ICHD) migraine headache days
omigraine attacks
omigraine headache hours
oheadache hours
oseverity  of remaining migrainesOverall m ean change from baseline ( during the 6 -
month double -blind treatment phase ) on the 
following monthly  measures:
oInternational Classification of Headache 
Disorders (ICHD) migraine headache days
omigraine attacks
omigraine headache hours
oheadache hours
oseverity  of remaining migraines
To compare LY2951742 with placebo with respect 
to global assessment of illnessOverall mean Patient Global Impression -
Improvement (PGI -I) rating during the 6 -month 
double -blind treatment phase
To compare LY2951742 with placebo with respect 
to changes in disability and quality of lifeMean change from baseline on the following 
measures:
othe Migraine Disability Assessment test 
(MIDAS) total score and individual items at 
Month 6
othe Migraine -Specific Quality of Life 
Questionnaire, version 2.1 (MSQ v2.1) total 
score, and Role Function -Preventive and 
Emotio nal Function domain scores (average of 
Months 4, 5,and 6)
To compare LY2951742 with placebo with respect 
to safety and tolerabilityAnaly sis of:
otreatment -emergent adverse events ( TEAEs )
odiscontinuation rates
ovital signs and weight
oelectrocardiograms (ECGs)
olaborato ry measures
oother safety parameters, including suicidality 
using the Columbia -Suicide Severity Rating 
Scale (C -SSRS)
I5Q-MC-CGAH (a)Clinical Protocol Page 16
LY2951742 Approved: 22 January 2016Table CGAH.1. Objectives and Endpoints (continued)
Objectives (cont.) Endpoints (cont.)
Other Secondary Objectives (cont.)
To evaluate LY2951742 with respect to 
immunogenicityThroughout the study:
oDevelopment and consequences of anti -drug 
antibodies and neutralizing anti -drug antibodies
to LY2951742 
To evaluate LY2951742 with respect to 
pharmacokineticsSerum concentrations of LY2951742
To evaluate LY2951742 with respect to 
pharmacodynamics (target engagement)Plasma concentrations of CGRP
To assess changes in efficacy outcomes during 
Study Period IV as collected by electronic patient -
reported outcomes (ePRO) diary dataIn Study  Period IV:
oMean change from baseline in monthly 
migraine headache days
oTime to first loss of response among patients 
who met the 50% response rate criteria at the 
end of the double -blind treatment phase
oTime to initiation of  treatment with a migraine 
prevention medication
Tertiary Objectives
To explore the effect of LY2951742 on n on-
migraine chronic painMean change from baseline in average pain severity 
of other chronic pain conditions
To compare LY2951742 with placebo with respect 
to categorical changes in quality of lifePercentages of patients with:
o≥50% improvement in MIDAS total score
ochange from baseline in MSQ Role Function -
Restrictive domain  ≥10.9
ochange from baseline in MSQ Role Function -
Preventive domain  ≥8.3
ochange from baseline in MSQ Emotional 
Function domain  ≥12.2
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 17
LY2951742 Approved: 22 January 2016Table CGAH.1. Objectives and Endpoints (continued)
Objectives (cont.) Endpoints (cont.)
Tertiary Objectives (cont .)
To compare LY2951742 with placebo with respect 
to the proportion of migraine headache days 
requiring medication for the acute treatment of 
migraine or headacheChange f rom baseline in the proportion of monthly  
migraine headache days requiring med ication for 
the acute treatment of migraine or headache
To compare LY2951742 with placebo with respect 
to changes in symptomatology associated with 
migraine or probable migraineChange f rom baseline in the number of monthly 
migraine headache days with:
onausea and/or vomiting
ophotophobia and phonophobia
oaura
oprodromal symptoms other than aura
I5Q-MC-CGAH (a)Clinical Protocol Page 18
LY2951742 Approved: 22 January 2016Table CGAH.2. Migraine and Headache Endpoint Definitions
Diagnosis Definition/Criteria
Migraine headache Aheadache, with or without aura, of ≥30 minutes duratio n
with both of the following required features (A and B) :
A.  At least 2 of the following headache characteristics:
Unilateral location
Pulsatile quality
Moderate or severe pain intensity
Aggravatio n by or causing avoidance of routine 
physical activity
AND
B.  During headache at least one of the following:
Nausea and/or vomiting
Photophobia and phonophobia
(Definition adapted from the Standard I nternational 
Headache Society [ IHS] International Classification of 
Headache Disorders (ICHD) -3 beta)
Probable migraine A headache missing 1 of the migraine features in the IHS 
ICHD -3 beta definition such that one feature in criteria A is 
missing or one feature in criteria B is missing; that is ,meet at 
least 2 A criteria and none of the B criteria or meet 1 of the A 
criteria and at least 1 of the B criteria .
Migraine headache day (primary objective) A calendar day on which a migraine headache or probable 
migraine headache occurred.
Migraine headache at tack Beginning on any  day a migraine headache or probable 
migraine headache is recorded and ends w hena migraine -free
day occurs.
Non-migraine headache All headaches of at least 30 minutes duration not fulfilling 
the definition of migraine or probable mig raine are classified 
as non -migraine headaches.
Non-migraine headache day A calendar day on which a non -migraine headache occurred.
Headache day A calendar day on which any type of headache occurs 
(including migraine headache, probable migraine headache ,
and no n-migraine headache).
I5Q-MC-CGAH (a)Clinical Protocol Page 19
LY2951742 Approved: 22 January 20164.Study  Design
4.1. Overview of Study Design
Study  CGAH (EVOLVE -2) is a Phase 3, multisite, double -blind, rando mized, placebo -
controlled, study  ofLY2951742 in pat ients suffering fro m episodi c migraine . The study  has4 
periods, i ncluding a prospective baseline phase to determine patient eligibilit y.
Figure CGAH .1illustrates the study design.
Figure CGAH .1. Illustration of study design for Clinical Protocol I5Q-MC-CGAH .
Study Period I: The study and potential risks will be explained to the patient at Visit 1.  The 
inform ed consent form  (ICF) m ust be si gned before any study  proced ures are perform ed.  
Patients are requi red to di scont inue all excluded medicat ions or migraine prevention treatments 
at least 30 days prior to Visit 2.  Botulinum toxin A or B in the head or neck area must be 
discontinued at least 4 months prior to Visit 2.Month 0 2 3
Visit        1 3a4 6 7
Dosing X X
RandomizationLY2951742 (120 mg)a
Placebo
Daily diary reportingSP I
Screening
5
10 51
X4
8
X X X6
128
1310
14 2--3-45
days
Month 
4.5
9 11SP II
BaselineSP III
Double -Blind
TreatmentSP IV
Follow -up
30-40*
days
*Eligibility period determined between a minimum of 30 days and a maximum of 40 days.  Investigators may have 
up to 5 additional days (beyond the 40 days) if needed to schedule patients’ Visit 3 appointment.
aPatients randomized to the 120 mg dose will receive a loading dose of 240 mg at the first injection only (Visit 3).
Abbreviations:  SP = study period.Month 0.5LY2951742 (240 mg)
Month 
5.5
I5Q-MC-CGAH (a)Clinical Protocol Page 20
LY2951742 Approved: 22 January 2016The screening visit (Visit 1) will consist of a full clinical assessment, including a comprehensive 
medical evaluat ion docum enting medical history , and a physical and neuro logical examination 
(Appendix 2 ).  Visit 1 will be co mplete when the last scheduled procedure of the screening 
assessment i s completed.
Study Period II : Qualified pat ients will enter Study  Period II (prospective baseline) to 
determine their eligibilit y for the study  and to establish baseline data for comparison of endpo ints 
during the treatment period.   Beginning at Visit 2, pati ents will  log in daily to the electronic 
patient-reported outcomes ( ePRO )system  to answer quest ions about the occurrence of 
headaches, headache duration, headache features , severit y of headache, and use of headache 
medicat ion.  At the end of the prospective baseline period, sites will be notified whether their 
patients m et cri teria and are eligible to be randomized at Visit 3.
To avoid biased reporting, patients must not be told the number of migraine headache days 
on which study qualification is based.
Study Period III: At the start of the 6 -monthdouble -blind treatment p hase ( Visit 3),patients 
meet ing all eligibilit y requi rements will be randomized to 1 of 3treatm ent groups in a 2:1:1 ratio 
to receive placebo, 120 m g/month LY2951742 , or 240 m g/month LY2951742, respect ively .
Patients randomized to the 120 mg dose of LY2951742 will rece ive an init ial loading dose of 
240 m g (2 inject ions of 120 m g each at Vi sit 3 only ). To preserve blinding throughout the study, 
patients in all treatm ent groups will receive 2 injections of invest igational product at each dosing 
visit (two pl acebo inject ions, two 120 -mg LY2951742 injections, or one placebo inject ion and 
one 120 -mg inject ion).  At Visit 3, if available and where local regulati ons and Ethical  Review 
Boards allow , patients will  also watch a training video designed to address patient expectati ons 
with regard to parti cipat ion in a placebo -controlled trial and the difference between medical 
treatm ent and research .
The patient will be considered enrolled in the study when rando mizat ion occurs.  During this 
phase , study  procedures at dosing visits must al ways occur pri or to the pati ent receiving their 
assigned treatment .
Patients will  be given inject ions of invest igational product during office visits (Figure CGAH .1).  
For all treatment groups, subcutaneous inject ionswill be administered once monthly at the 
dosing visits.  A t Visi t 3(first dose) , pati ents will be requi red to rem ain in the office for 
observat ionfor 30 minutes post inject ion.  Pati ents will cont inue to log in and com plete the 
ePRO diary each day .  Patients m ay cont inue to take thei r allowed acute migraine headache 
medicat ion(with som e limi tations; see Secti on 6.8)during the treatment phase.
Patients who com plete thi s phase or discont inue for any  reason during Study  Period III will be 
expected to enter post -treatm ent follow-up (Study  Period IV).
Study Period IV : Durin g this 4-month phase, si tes and pat ients will remain blinded to patients’ 
treatm ent assi gnments.  Pati ents will  follow all study  procedures during Study  Period IV but will 
not receive LY2951742 or placebo. One month after Visit 12, if clinically warranted due to a 
worsenin g of symptom s, patients may  start mi graine preventi on medicat ions at the discretion of 
I5Q-MC-CGAH (a)Clinical Protocol Page 21
LY2951742 Approved: 22 January 2016the invest igator.  The list of allowed prevent ive medications is provided in Section 6.8.  At Visit 
14 (Mon th 10), pati ents will return to the site for their last study  visit and discharge from  the 
study .
4.2. End of Trial Definition
End of the trialis the date of the last visit or l ast scheduled procedure shown in the Schedule of 
Activities(Appendix 2 )for the last patient.
4.3. Scientific Rationale for Study Design
The l ength of the rando mized treatment phase is considered sufficient to assess the safet y and 
efficacy  of a migraine prevent ion medicat ion and is consistent with regulatory  feedback. A 4-
month post -treatm ent follow-up phase is included to evaluate patient safety  durin g wash -out of 
LY2951742. This allo ws for a total of 5 months of observat ion from the time of last inject ion of 
LY2951742.  A 5 -month post -treatment observat ion peri od all ows f or a wash -out of 
approximately  5 eliminat ion half-lives of LY2951742 and should decrease LY2951742 serum 
concentrations by approximately 97% during this time.
4.4. Justification for Dose
Doses of 120 and 240 mg a dministered once monthly were selected primarily on the basis of 
clinical efficacy  and pharmacokinet ic/pharmacodynamic data fro m the Phase 2 dose -ranging 
study .  Results fro m the Phase 2 dose -ranging study indicate that 120 mg was statistically 
significant ly superi or to pl acebo at the l ast 28 -day period of the 3 -month treatm ent phase in 
mean change in migraine headache da ys, as well as in other measures of efficacy and qualit y of 
life.  The use of a loading dose for the 120 mg treatment arm, and the inclusio n of a 240 mg 
treatm ent arm , is based on the finding that a dose higher than 120 mg achieved statistically 
significant separati on from placebo as early as Month 1.  The pl anned doses of 120 mg and 240 
mg LY2951742 for Study  CGAH also are being evaluated in two other pivotal efficacy studies 
of LY2951742; one of these studies is in pat ients with episodi c migraine, and one is in pat ients 
with chroni c migraine .
4.5. Benefit/Risk Assessment
More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably ant icipated adverse events (AEs) of LY2951742 are to be found in th e 
Invest igator’s B rochure (IB).
I5Q-MC-CGAH (a)Clinical Protocol Page 22
LY2951742 Approved: 22 January 20165.Study  Population
All patients must meet the fo llowing select ion criteria.  Eligibilit y of patients for study  
enrollment will be based on the results of a screening medical history, physical examinat ion, 
neuro logical examinati on, clinical labo ratory  tests, electrocardi ograms ( ECG s), and migraine 
history  during screening and a prospective baseline period, as described in the Inclusio n and 
Exclusio n Cri teria sect ions.  The nature of any comorbid condit ions present at the time of the 
physical exam ination and any  pre-exist ing condit ions must be documented.   Individuals who do 
not m eet the cri teria for parti cipat ion in this study  (screen failure) for specific reasons as outlined 
may be considered for rescreen ing once, with approval fro m Eli Lilly and Company ( Lilly )
Medical (Sect ion 5.3).
Study  parti cipants shoul d be instructed not to donate blood or blood products during the study or 
for 5 m onths following last administration of investigat ional product.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are notpermitted.
5.1. Inclusion Criteria
Patients are eligible to b e included in the study  only  if they  meet all  of the f ollowing criteria at
screening :
Patient and Disease Characteristics
[1] Patients are 18 to 65 y ears of age (inclusive) at the time of screening.
[2] Have a diagnosis of migraine as defined by  Internati onal Headache Soci ety 
(IHS) International Classificat ion of Headache Disorders (ICHD) -3 beta 
guidelines (1.1 or1.2) ( ICHD -3 2013) , with a history of migraine headaches
of at least 1 year prior to Visit 1 , and migraine onset prior to age 50.
[3] Prior to Vi sit 1, have a history  of 4 to 14 migraine headache days and at least 
2 migraine attacks per month on average wit hin the past 3 months.
[4] From  Visi t 2 to Visi t 3 (prospective baseline period), have a frequency of 4 to 
14 migraine h eadache days and at least 2 migraine attacks (see definit ions, 
Table CGA H.1).To avoid biased reporting, patients must not be told the 
number of migraine headache days on which study qualification is based.
[5] From  Visi t 2 to Visi t 3 (prospective baseline period), must achieve sufficient 
compliance wi th ePRO daily headache entries as demonstrated by  com pletion 
of at least 80% of daily diary  entries.
Informed Consent and Patient Agreements
[6] Are able and willing to give signed informed consent.
[7] Are reliable an d willing to follow study  procedures, including all fo llow-up 
visits.
I5Q-MC-CGAH (a)Clinical Protocol Page 23
LY2951742 Approved: 22 January 2016[8] Women of child -bearing potenti almust test negative for pregnancy  at the time 
of enro llment based on a serum pregnancy test .
[9] All patients, male and female, must agree to use a re liable method of birth 
control  during the study as well as for 5 months after the last dose of 
investigat ional product . Acceptable methods of birth control for this study 
include :  oral contraceptives; implantable contraceptives; injectable 
contraceptives ; a contraceptive patch; barrier methods such as diaphragms 
with contracepti ve jelly, cervical caps wit h contraceptive jelly, condo ms with 
contraceptive foam, or intrauterine devices; a partner with vasectomy .  Birth 
control  is not requi red if the f emale isinfertile due to surgical sterilizat ion (at 
least 6 weeks after surgical bilateral oophorectomy , hysterectomy ,or at least 6 
weeks after tubal  ligat ion) confirmed by medical history  or m enopause.  
Menopause is defined as spontaneous amenorrhea for at le ast 12 m onths not 
induced by  a medical condi tion, or spontaneous amenorrhea of 6 -12 m onths 
and a fo llicle st imulating hormone level >40 mIU/mL .
[10] Agree not to post any  personal medical data rel ated to the study  or 
inform ation related to the study  on any websi te or soci al media si te (for 
example, Facebook, Twitter, LinkedIn, Google +, etc.) until the entire trial has 
completed.
5.2. Exclusion Criteria
Patients will  be excluded from  study  enro llment if they meet any o f the following cri teria at
screening:
Prior/ Concurrent Clinical Trial Experience
[11] Are current ly enrolled in any other clinical trial invo lving an invest igational 
product or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study.
[12] Have part icipated wi thin the l ast 30 day s or wi thin 5 half -lives (whichever is 
longer) in a clinical trial invo lving an invest igational product.  If the 
investigat ional product’s half- life is not known, 6 mo nths should have passed 
prior to Visit 1.
[13] Current use or pri or exposure to LY2951742 or another CGRP antibody , 
including those who have previously completed or withdrawn from this study  
or any  other study  invest igating a CGRP antibody.
Prior/Concomitant Therapy
[14] Patients who are taking, or are expected to take, therapeutic ant ibodies during 
the course of the study  (for example, adalimumab, infliximab, trastuzumab, 
bevacizumab, etc.).  Prior use of therapeutic ant ibodies, other than ant ibodies 
to CGRP or i ts receptor, is allowed if that use was more than 12 months prior 
to Visit 2.
I5Q-MC-CGAH (a)Clinical Protocol Page 24
LY2951742 Approved: 22 January 2016[15] Known h ypersensit ivity to multip le drugs, m onoclonal  antibodies or other 
therapeuti c proteins, or to LY2951742 .
[16] Are current ly receiving medicat ion or other treatments for the prevent ion of 
migraine headaches.  Patients must have discont inued such treatment at least 
30 day s prior to Vi sit 2.  Botulinum  toxin A and B that has been administered 
in the head or neck area must be di scont inued at least 4 months prior to 
Visit 2.
[17] Failure to respond to 3or more adequately dosed migraine prevent ive 
treatm ents fro m different classes (that is, maximum tolerated dose for at least 
2 months). Failure to respond due to tolera bility issues is not considered a 
treatm ent failure.  M igraine prevent ivetreatm ents are defined as Level A and 
Level B in Table 1 of the American Academy of Neurology ’s Evidence -based 
Guidelines Update:  Pharmaco logic Treatm ent for Episodi c Migraine 
Preve ntion in Adults (Silberstein et al. 2012 )as well as botulinum toxin A or 
B.
Diagnostics Assessments
[18] History  of persistent daily  headache, cl uster headache or migraine subt ypes 
including hemiplegic (sporadic or familial) migraine, ophthalmoplegic 
migraine, and  migraine with brainstem  aura (basilar -type migraine) defined 
by IHS ICHD -3 beta.
[19] History  of headache (for example, cluster headache, Medicat ion Ove ruse 
Headache ) other than migraine or tension t ype headache as defined by IHS 
ICHD -3 beta within 3 mo nths prior to randomization.
[20] Prior to Vi sit 1, a history  of ≥15 headache days (migraine, probable migraine 
orany other headache) per month on averag e during the past 3 months or are 
suspected of suffering fro m chronic migraine as defined per ICHD -3 beta.
[21] History  of head or neck injury  within 6 m onths prior to Vi sit 1.
[22] Patients wi th a history  of traum atic head injury associated with significa nt 
change in the qualit y or frequency of their headaches should be excluded.
Medical Conditions
[23] Have ECGs showing abnorm alities com patible wit h acute cardiovascular 
events and/or serious cardiovascular risk, including but not limited to a 
corrected QT (QTcB [Bazett's] ) interval > 470 m sec for wom en and >450 for 
men, or have had my ocardial  infarcti on, unstable angina, percutaneous 
coronary  intervent ion, coronary  artery  bypass graft, or deep vein 
thrombosis/pulmo nary embo lism wit hin 6 months of screening , or have 
planned cardio vascular surgery or percutaneous coronary  angi oplasty , or 
patients wi th a lifet ime history  of stroke .
[24] Patients wi th a body  mass index ≥40 kg/m2.
I5Q-MC-CGAH (a)Clinical Protocol Page 25
LY2951742 Approved: 22 January 2016[25] Any liver tests outsi de the norm al range at Vi sit 1 that are clinically 
significant .  Alanine aminotransferase (ALT) >2X upper limit of norm al 
(ULN), ortotal bilirubin (TBL) >1.5X ULN , or alkaline phosphatase (ALP) 
>2X ULN m ust be discussed and judged not clinically significant by  Lilly  
Medical prior to enrollment .
[26] Evidence o f significant active or unstable psychiatri c disease by medical 
history , such as bipo lar disorder , schizophrenia, personalit y disorders, or other 
serious moodor anxiet y disorders. Note : Patients with major depressive 
disorder or generalized anxiet y disorder whose disease state is considered 
stable and expected to remain stable throughout th e course of the study , in the 
opinio n of the invest igator, may be considered for inclusio n if they are not on 
excluded medicat ions.
[27] Patients who, in the clini cian’s j udgment, are actively suicidal and therefore 
deem ed to be at si gnificant ri sk for sui cide, or those who have answered “yes”
to either Question 4 (Act ive Suicidal Ideat ion with Som e Intent to Act, 
Without Specific Plan) or Question 5 (Act ive Suicida l Ideati on wi th Specific 
Plan and Intent) on the “Suicidal  Ideat ion”portion of  the Columbia Sui cide 
Severit y Rating Scale (C–SSRS ), or answer “yes”to any  of the sui cide-related 
behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory  
act or behavior) on the “Suicidal Behavior” portion of  the C –SSRS; and the 
ideat ion or behavior occurred within the past month.
[28] Women who are pregnant or nursing.
[29] Patients who have used opioids or barbiturate containing analgesic >2 Xper 
month for the treatment of pain in more than 2 of the past 6 months (opioid 
administration in an emergency  setti ng may be an exception) .
[30] History  of drug or alcoho labuse/dependence wit hin 1 y ear pri or to Vi sit 1 
(excessive or compulsive use as judged by  the I nvestigator), or currently using 
drugs of abuse (including opio ids, barbiturates and marijuana), or any 
prescribed or over- the-counter medicat ion in a manner that the Investigator 
considers indicat ive o f abuse/dependence.
[31] Have a posit ive urine drug sc reen for any  substances of abuse at Visit 1 .  
Note :  A retest is allowed if the urine drug screen is posit ive for any  
prescribed substance or if, in the judgment of the investigator, there is an 
acceptable explanat ion for the posit ive result .  The results of the retest must be 
negat ive at or pri or to Vi sit 2.
[32] Have a history  or presence of any other medical  illness including but not 
limited to any  autoimmune disorder, cardiovascular, hepatic, respiratory , 
hematol ogical, endocrine, psychiatric or neurolo gical  disease, or any  clinically  
significant laboratory  abnorm ality, that in the judgment of the investigator, 
indicates a medical problem that woul d preclude study  parti cipat ion.
I5Q-MC-CGAH (a)Clinical Protocol Page 26
LY2951742 Approved: 22 January 2016Other Exclusions
[33] In the opinion o f the invest igator have other issues which woul d interfere wi th 
compliance wi th the study  requi rements and com pletion of  evaluat ions 
requi red for thi s study .
[34] A re invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted .
[35] A re Lilly  empl oyees.
[36] A re unwilling or unable to comply  with the use of a data collect ion device .
5.3. Screen Failures
Individuals who do not meet the criteria for participa tion in this study  (screen failure) m ay be
considered for rescreen once, wi th approval  from Lilly Medical  for only  the cri teria shown 
below.  The interval between screening and rescreening mustbe at l east 45 days or longer if 
requi red for the specified timeframes in the inclusion/exclusion criteria or concomitant 
medicat ionsrequi rements .  If rescreening is performed, the individual must si gn a new ICF and
will be assigned a new ident ificat ion number.
Inclusio n criterion 1.  If pati ents are l ess than age 18 at time of informed consent, 
they may be rescreened if they reach age 18 during the study  enrollment peri od.
Inclusio n criterion 8 
Exclusio n criterion 12
Exclusio n criterion 14
Exclusio n criterion 16
Exclusio n criterion 28
Patients using a concomitant medication that requires a stable dose for a specific durat ion prior 
to Visit 2 may  be rescreened if addit ional time is needed to meet the duration requirement.
In addit ion, after consultation wit h and approval by a Lilly Medical representative, a patient may 
be rescreened if there is an unexpected technical difficult y with the el ectronic di ary capture 
during the prospective baseline period.
5.4. Lifestyle and/or Dietary Requirements
No changes in lifestyle or dietary  requi rements are requi red during the study .  However, patients 
must be in a fast ing state for collect ion of laboratory samples at selected visit s specified in 
Appe ndix 2 .
I5Q-MC-CGAH (a)Clinical Protocol Page 27
LY2951742 Approved: 22 January 20166.Treatment
6.1. Treatments Administered
This study  involves a comparison of LY2951742 (120 and 240 mg) administered once m onthly  
with placebo.  Si tes will  administer inject ions of investi gational product (LY2951742 and/or 
placebo) at6 office visits during the treatment p hase ( Appendix 2 ).
Possible inject ion sites include the abdo men, thi gh, and upper arm .  Buttocks may  also be used, 
if needed .
The invest igator or his/her desi gnee is responsible for the following:
maintaining accurate records of investigational product dispensing
at the end of the study  returning all unused medication to Lilly ,or its desi gnee ,
unless the sponsor and sites have agreed all unused medicat ion is to be destroy ed 
by the site, as allowed by local law .
6.1.1. Medical Devices
The m anufactured medical devices provided for use in the study  are prefilled syringes.
6.2. Method of Treatment Assignment
Patients who m eet all cri teria for enrollment will be randomized to double -blind treatment at
Visit 3.  Assignment to treatment groups w ill be determined by a computer -generated random 
sequence using an interactive web -response system (IWRS).   The IWRS will be used to assi gn
doubl e-blind investigat ional product to each pat ient. Site personnel will confirm that they  have 
located the correct ly assigned package by entering the confirmat ion number found on the
package into the IWRS.
To achieve between -group com parabilit y, the randomizat ion will be stratified by  country and 
baseline migraine frequency (<8 migraine headache day s versus ≥8 migraine headache days) .  To 
ensure an appropriate balance o f low-and high -frequency migraine headache day patients, the
sponsor willstop enrollment oflow-frequency patients ifthenumber exceeds anestimated 578.
6.2.1. Selection and Timing of Doses
This is a fixed -dose study .  The actual time of all dose administrations will be recorded in the 
patient’s electroni c case report form ( eCRF) .
6.3. Blinding
This is a double -blind study .
To preserve the blind ing of the study , a minimum number of Lilly  personnel  will see the 
rando mizat ion table and treatment assignments before the study  is complete.
I5Q-MC-CGAH (a)Clinical Protocol Page 28
LY2951742 Approved: 22 January 2016Emergency  unblinding for AEs m ay be perform ed through the IWRS .  This option may be used 
ONLY if the patient’s well-being requires knowledge of the patient’s treatment assignment .  All
unblinding events are recorded and reported by  theIWRS .
If an invest igator, site personnel performing assessments, or patient is unblinded, the patient 
must be discont inued fro m thestudy .  In cases where there are ethical reasons to have the patient 
remain in the study , the investigator must obtain specific approval fro m a Lilly clinical research 
physician (CRP) or clinical research scient ist (CRS) for the patient to continue in the study .
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a pati ent’s treatm ent assignment is warranted. Patient safet y must always be the first 
consideration in making such a determinat ion.If an emer gency  unblinding occurs, Lilly must be 
notified as soon as possible.
6.4. Packaging and Labelling
LY2951742 and matching placebo (excipients only) will be supplied as an injectable so lution in 
1-mL, single -dose, prefilled, disposable manual syringes wit h study  specific labels. Each sy ringe 
of LY2951742 is designed to deliver LY2951742 120 m g.  The sy ringes (and contents) 
containing either LY2951742 or placebo will be visibly indist inguishable fro m each 
other. Syringes will be supplied in cartons, with the appr opriate quant ity of syringes specific to 
the planned dispensing schedule of invest igational product .
Clinical trial materials will be labeled according to the country ’s regul atory  requi rements.
6.5. Preparation/Handling/Storage
Invest igational product will be s hipped (as prefilled sy ringes) to si tes using c old chain 
transportation.   Invest igational product must be stable and stored in a refrigerator at 2ºC to 8ºC 
(35.6ºF to 46.4ºF) .
Approximately  30 minutes prior to administration, the syringeshoul d be rem oved f rom the 
storage area and allowed to equilibrate at ambient condit ions.  The d rug product shoul dbe kept 
away  from direct exposure to bri ght light (such as sunlight) and hot surfaces until administration.
6.6. Dose Modification
Dose m odificat ions are not permitted in this study .
6.6.1. Special Treatment Considerations
During the post -treatment follow -up peri od, p atients will not receive LY2951742 or pl acebo . 
One mo nth after Visit 12, if clinically warranted due to a worsening of symptoms, patients m ay 
start migraine prevent ion medications at the discretion of the investigator.  The list of allo wed 
prevent ive medicat ions is provided separately .
6.7. Treatment Compliance
Invest igators will be required to document the administration of invest igational produc t in the 
eCRF.
I5Q-MC-CGAH (a)Clinical Protocol Page 29
LY2951742 Approved: 22 January 2016Invest igational product must be administered as indicated in the Schedule of Act ivities
(Appendix 2 ).  If the invest igator is unable to administer the investigational product in the 
allowed window, then the situation shoul d be discussed with Lilly to determine if the patient may  
continue.
6.8. Concomitant Therapy
Table CGA H.3contains a list of medicat ions that are, and are not, allowed in this study. Note 
that acute treatment of migraine headache is allowed throughout the study but with so me 
limitations.  Treatm ents used for the prevent ion of migraine are not allowed at any  time during 
Study  Periods I through III.
Table CGAH.3. Treatments Allowed and Treatments Not Allowed as Concomitant 
Therapy
Medications allowed for the ACUTE treatment of migraine headaches or other pain or 
injury:
Acetaminophen (paracetamol), NSAIDs; Triptans; Ergotamine and derivatives; Isometheptene mucate, 
dichloralphenazone and acetaminophen combination (Midrin); or combinations thereof.
The following medications are allowed with restrictions:
1.Opioid and barbiturates no more than 3 days/month (SP II, III and IV).
2.Single dose of injectable steroids allowed only once during the study, in an emergency setting (SP III and IV).
Medication s, Procedures or Devices not al lowed for any reaso n/indication :
Acetazolamide
Acupuncture
Anticonvulsants/Antiepileptics
Antipsychotics
Beta-blockers
Botulinum toxin applied to head/neck area
Cannabis / Cannabinoids
Chiropractic procedures, physiotherapy, TENS or other electric devices on head and neck
Corticost eroids for oral use
Flunarizine
Herbals with anti -inflammatory effect (feverfew, willow bark, petasites/butterbur), herbals with sympathomimetic 
effect (ma huang, ephedra, bitter orange, synephrine) and herbals with catecholamine transmitter reuptake 
inhibition (St John’s Wort)
Mon oamine oxidase inhibitors (MAOIs)
Memantine
Serotonin 5HT2a/2c antagonists, e.g.:  trazodone, nefazodone
Stimulants (prescription strength), e.g.:  methy lphenidate, dextroamphetamine, mixed amphetamine salts
Tizanidine
Therapeutic an tibodies, e.g.:  adalimumab, infliximab, trastuzumab, bevacizumab, etanercept, etc.
Tricyclic antidepressants (TCAs)
Triptans for prophylaxis of menstrual related migraine
Venlafaxine
Verapamil
I5Q-MC-CGAH (a)Clinical Protocol Page 30
LY2951742 Approved: 22 January 2016Table CGAH. 3. Treatments Allowed and Treatments Not Allowed as Concomitant 
Therapy (continued)
Restricted medication during SP II -III:  Use of the following medications for indications 
other than migraine prevention is allowed providing the dose is stable 2 months prior to 
Visit 2and is expected to remain stable during V isit 2through 12.
ACE inhib itors
Angiotensin receptor blockers (ARBs)
Benzodiazepines
Bupropion 
Calcium -channel blockers (except verapamil and flunarizine)
Clonidine
Guanfacine
Mirtazapine
SSRIs/NRIs/SNRIs (other than venlafaxine)
Use of electric devices (i.e. TENS), physiothe rapy, chiropractic procedures on low back and extremities
Restricted medication during SP II -III:  Use of the following medicat ions for indications 
other than migraine prevention is allowed :
Beta-blockers, op hthalmic
Cyclandelate
Cyproheptadine
Melatonin
SP IV (After V isit 12)
One month after Visit 12, if clinically warranted due to a worsening of symptoms, patients may start migraine 
prevention medications at the discretion of the investigator with the exception of antipsychotics, cannabis and 
cannabinoids, MAO Is, memantine, se rotonin 5HT2a/2c antagonists, and stimulants, which remain excluded.
6.9. Treatment after Study Completion
6.9.1. Study Extensions
Not applicable.
6.9.2. Continued Access
Invest igational product will not be m ade available to patients after concl usion of the study .
I5Q-MC-CGAH (a)Clinical Protocol Page 31
LY2951742 Approved: 22 January 20167.Discontinuation Criteria
Patients who discont inue the study or invest igational product during the double -blind treatment 
phase (Study  Period III) will proceed immediately to Study  Period IV.
7.1. Discontinuation from Study Treatment
7.1.1. Permanent Discontinuation fr om Study Treatment
Discontinuati on of  the invest igational product is required in cases of pregnancy.
Discontinuati on of  the invest igational product for abnormal liver tests is required when a pati ent 
meets one of the fo llowing condi tions and the event is at least possibly related to study drug :
ALT or aspartate aminotransferase (AST) >8X ULN
ALT or AST >5X ULN for more than 2 weeks
ALT or AST >3X ULN and TBL >2X ULN or prothrombin t ime >1.5X ULN
ALT or AST >3X ULN with the appearance of fat igue, nausea , vomi ting, ri ght 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
ALP >3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.5X ULN with the appearance of fatigue, nausea, vo miting, right quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%)
Discontinuati on of  investigat ional product also is required in the following cases, if the event i s 
at least possibly related t o study drug:
Serious allergi c react ion to study  drug
Serious injection -site reacti on
Serious event of suicidalit y or depressi on
Serious cerebrovascular event .
Patients who discont inue the invest igational product early  will have end -of-therapy  (early 
termi nation) procedures performed as shown in the Schedule of Activit ies(Appendix 2 )and are 
requested to proceed into the post -treatm ent phase .
7.1.2. Tempor ary Discontinuation from Study Treatment
Not applicable.
7.1.3. Discontinuation of Inadvertently Enrolled Patients
If the sponsor or invest igator ident ifiesa pati ent who di d not m eet enrollment cri teria and was 
inadvertent ly enro lled, a discussio n must occur between the sponsor CRP /CRS and the 
investigator to determine if the pat ient may cont inue in the study .  If both agree i t is medically  
appropriate to co ntinue, the invest igator must obtain documented approval fro m the sponsor 
I5Q-MC-CGAH (a)Clinical Protocol Page 32
LY2951742 Approved: 22 January 2016CRP /CRS to allow the inadvertent ly enro lled patient to continue in the study  with or wi thout 
treatm ent wi th invest igational product.
7.1.4. Permanent Discontinuation from the Study
Some pos sible reasons that may lead to permanent discontinuat ion include:
Enrollment in any other clinical trial invo lving an investigational product or enrollment in 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study
Participation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
Invest igator Decisio n
othe invest igator decides that the patient should be discontinued from the study
oif the pat ient, for any  reason, requi res treatm ent with another therapeutic agent that 
has been demonstrated to be effect ive for the study indication (preventi on of  
migraine) during Study  Period III ,discontinuat ion from thestudy  occurs pri or to 
introducti on of  the new agent
Subject Decisio n
othe patient asks to be wi thdrawn from  the study
Patients who discont inue the study early will have end -of-study  (early  terminati on) procedures 
perform ed as shown in the Schedule of Activities(Appendix 2 )and are requested to proceed into 
the post -treatment phase .
7.1.5. Patients Lost to Follow -Up
A pat ient willbe considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact patients who fail to return for a scheduled vis it or were otherwise 
unable to be fo llowed up by  the si te.
I5Q-MC-CGAH (a)Clinical Protocol Page 33
LY2951742 Approved: 22 January 20168.Study  Assessments and Procedures
Appendix 2 lists the Schedule of Act ivities, with the study  procedures and their timing (including 
tolerance limit s for timing).
Appendix 3 lists the laboratory tests that wi ll be perform ed for this study .
Appendix 4 lists the tests that may be obtained in the event of a treatment -emergent hepatic 
abnorm ality.
Unless otherwise stated in the sub sections below, all samples collected for specified laboratory 
tests will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.
8.1. Efficacy Assessments
8.1.1. Primary Efficacy Assessments 
ePRO Di ary:  Pati ents will be asked to use an ePRO device (starting at Visit 2) to record 
headache symptoms, duration, and severit y.  The device also will be used to col lect the name and 
dose of conco mitant m edicat ions used for the acute treatment of migraine, and the use of other 
pain medicat ions.
8.1.2. Secondary Efficacy Assessments
8.1.2.1. Patient Global Impression of Severity
The Pati ent Gl obal Impressi on of Severi ty (PGI -S) scale (Guy 1976) is a pati ent-rated instrument 
that measures baseline illness severit y.  The PGI -S includes a range of possible responses, fro m 1 
(“normal, not at all ill”) to 7 (“extremely ill”).
8.1.2.2. Patient Global Impression of Improvement
The Pati ent Gl obal Impressio n of Im provement (PGI -I) scale ( Guy 1976) i s a patient -rated
instrum ent that m easures improvement of the patient’s symptoms.  It is a 7- point scale in which a 
score of 1 i ndicates the patient is “very  muchbetter ,” a score of 4 indicates the patie nt has 
experienced “no change,” and a score of 7 indicates the patient is “very  much worse.”
8.1.3. Appropriateness of Assessments
All efficacy and safet y assessments have been well documented and are generally  regarded as
reliable, accurate, and relevant in this patient population .  Thi s includes healt h outcom es 
measures considered to be appropriate for evaluat ing changes in qualit y of life, global 
funct ioning, and disabilit y (Section 8.9).
I5Q-MC-CGAH (a)Clinical Protocol Page 34
LY2951742 Approved: 22 January 20168.2. Adverse Events
Invest igators are responsible for monitoring the safety of pat ients who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered a n unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medical care of pat ients during the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for following, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or that caused the patient to discontinue the invest igational product before 
completing the study .  The pati ent shoul d be f ollowed unt il the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency o f follow-up 
evaluat ions of the AE is left to the discret ion of the invest igator.
Lack o f drug effect i s not an AE in clinical studies, because the purpose of the clinical study  is to 
establish treatment effect.
After the ICF is signed, study  site personnel will record via eCRF the occurrence and nature of 
each patient’s pre-exist ing condi tion(s), including clinically significant signs and symptoms of 
the disease under treatment in the study .  In addi tion, si te personnel will record via eCRF any 
change in the condit ion(s) and any new condit ion(s) asAEs. Invest igators should record th eir 
assessment of the potential relatedness of each AE to protocol procedure orinvest igational 
product via eCRF .
The invest igator will decide whether he or she interprets the observed AEs as reasonably 
possibly  related to migraine headache, to the investi gational product, study  device, study  
procedure, or other concomitant treatment or pathologies.
The invest igator will answer y es/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underl ying m edical condit ion has worsened during the course of the study .
If a patient’s investigational product is discontinued as a result of an AE, study  site personnel  
must report this to Lilly or its designee via eCRF , clarifying if possible, the circumstan ces 
leading to discontinuations of treatm ent.
8.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospitalizat ion
a life -threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
I5Q-MC-CGAH (a)Clinical Protocol Page 35
LY2951742 Approved: 22 January 2016congenital ano maly/birth defect
considered significant by  the invest igator for any other reason:  important medical 
events that may  not resul t in death, be life -threatening, or require hospitalizat ion 
may be considered serious, based upon appropriate medical judgment
when a condit ion related to the invest igational device ( for example, prefilled 
syringe) necessitates m edical or surgi cal intervent ion to preclude either permanent 
impairment of a body  function or permanent damage to a body  structure, the 
serious outcom e of “requi red intervent ion” will be assigned
Although all AEs after signing the ICF are recorded in the eCRF, SAE reporti ng begins after the 
patient has signed the ICF and has received investigational product.  However, if an SAE occurs 
after si gning the ICF, but prior to receiving investigational product, it needs to be reported 
ONLY if it is considered reasonably possibly related to study  procedure.
Study  site personnel  must al ert Lill y or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 24 -
hour notificat ion requirement refers to the init ial SAE informat ion and all fo llow -up SAE 
inform ation.
Pregnancy (during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE.  However, to fulfill regulatory requireme nts,any pregnancy that occurs 
during the study , including those in which conceptio n occurred within 5 months after last 
administration of invest igational product, should be reported using the SAE process to collect 
data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in patientsonce they  have 
discontinued and/or completed the study  (the patientsummary eCRF has been com pleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a patienthas 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .
8.2.1.1. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to investigational product or procedure.  
United States 21 CFR 312.32 and European Unio n Clinical Trial Direct ive 2001/20/EC and the 
associ ated detailed guidance or nati onal regulatory requi rements in parti cipat ing countries 
requi re the reporting of SUSARs . Lilly has procedures that will be fo llowed for the recording 
and expedited reporting of SUSARs that are consistent with glo bal regulat ions and the associated 
detailed guidance.
8.2.1.2. Adverse Event Monitoring with a Systematic Questionnaire
Suicidali ty will be assessed as requi red by the US Food and Drug Administration’s Divisio n of 
Neurol ogy for use in clinical trials invo lving all drugs for neurological indicat ions. Before 
administering the C-SSRS )[Posner et al. 2011]) , study site personnel  will quest ion the patient 
I5Q-MC-CGAH (a)Clinical Protocol Page 36
LY2951742 Approved: 22 January 2016about any  change in the pre-exist ing condit ion(s) and the occurrence and nature of any AEs.  
Nonserious AEs obtained through the questionnaire are recorded and analyzed separately. Only 
serious AEs and AEs leading to discont inuat ion elici ted through the C -SSRS are to be recorded 
as AEs via eCRF .  Serious adverse events must be reported to Lilly  or its designee wi thin 
24hours as SAEs.  Any suicidal behavior, or suicidal ideat ion per items 4 or 5 (active suicidal 
ideation with som e intent to act, ei ther wi thout specific pl an or wi th specific pl an and intent) 
woul d prom pt ref erral of the pati ent to a m ental  health prof essional.
8.2.2. Complaint Handling
Lilly co llects product complaints on invest igational products and drug de livery systems used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Patients will  be instructed to contact the investigator as soon as possible if he or she has a
complaint or probl em wi th the invest igational product (or drug delivery  system such as a 
prefilled syringe ) so that the situation can be assessed.
8.3. Treatment of Overdose
No data are available at this stage of development .
8.4. Safety Assessments
8.4.1. Electrocardiogr ams
For each patient, a single, 12 -lead digital ECG will be collected at the visits shown in the 
Schedule of Activities (Appendix 2 ). Electrocardi ogram s will have a central overread and 
shoul d be recorded according to the study -specific recommendat ionsincluded in the ECG
manual.
Any clinically  significant findings from ECGs that result in a diagnosis should be reported to 
Lilly or i ts designee as an AE viaeCRF .
8.4.2. Vital Signs
Vital signs will  include body  temperature, bl ood pressure, and pulse.  Blood pressure and pulse 
will be measured in triplicate in the sitt ing posit ion prior to bl ood draws and study drug 
administration (see Study  Schedule [ Appendix 2 ]).
Any clinically  significant findings from vital signs measurement that result in a diagnosis should 
be reported to Lilly or its designee as an AE viaeCRF .
8.4.3. Laboratory Tests
For each patient, laboratory testsdetailed in Appendix 3 shoul d be conducted accordi ng to the 
Schedu le of Activities (Appendix 2 ).
Any clinically  significant findings from laboratory tests that resul t in a di agnosis shoul d be 
reported to Lilly  or its designee as an AE via eCRF .
I5Q-MC-CGAH (a)Clinical Protocol Page 37
LY2951742 Approved: 22 January 2016In addit ion, an immunogenicit y plasma sam ple will  be collected, when possible, for any  patient 
who experiences a potential systemic allergic/hypersensit ivity react ion during the study  as 
judged by  the invest igator. This immunogenicit y plasma sample shoul d be co llected 
immediately  or as soon as p ossible, taking into consideration the availabilit y and wellbeing o f 
the pati ent. Exact date and time of the sample should be recorded on the laboratory requisit ion 
form.
8.4.4. Other Tests
Not applicable.
8.4.5. Safety Monitoring
Invest igators are responsible for moni toring individual  patient safety  throughout the tri al.If a 
study  patient/subject experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or elevated 
TBL ≥2X ULN, clinical and laboratory  monitoring shoul d be ini tiated by  the 
investigator. Details for hepat ic monitoring depend upon the severit y and persistence of 
observed laboratory  test abnorm alities. To ensure patient/subject safety and co mply with 
regul atory  guidance, the invest igator is to consult with the Lilly CRP/CRS regarding collect ion 
of specific reco mme nded clinical information and fo llow-up laboratory  tests. See Appendix 4 .
Neurol ogical examinat ions will be conducted at screening, Month 3 and Month 6 of treatment, as 
well as at the final visit of the fo llow-up peri od or early  terminat ion visit in order to assess for 
any signs o f pre-exist ing or treatment -emergent neurol ogical  abnorm alities such as stroke or 
other cerebrovascular events.  If a s tudy patient experiences signs of a cerebrovascular event, 
appropriate fo llow-up and clinical management should be conducted by  the investi gator, and the 
Lilly CRP/CRS should be consulted regarding co llection of further clinical informat ion and 
follow-up testing.
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by appropri ate 
blinded methods .  In addition, safet y data for the trial will also be reviewed periodically  by an 
independent Data Monitoring Co mmittee ( DMC; an advisory  group for this study  formed to 
protect the integrit y of data; refer to Interim Analyses sect ion[Secti on 9.8]).  In the event that 
safet y monitoring uncovers an issue that needs to be addressed by unblinding at the group leve l, 
members of the DMC can request additional analyses of the safet y data.
8.5. Pharmacokinetics
At the visit s and t imes specified in the Schedule of Act ivities (Appendix 2 ), venous blood
samples of approximately 2.5 mL each will be collected to determine the serum concentrati ons 
of LY2951742 .  A maximum o f 3 sam ples m ay be collected at addi tional time points during the 
study  if warranted and agreed upon between both the investigator and sponsor.  Instructions for 
the collect ion and handling of blood samples will be provided by the sponsor.
When a blood sample is collected , the time and date of last dose administration prior to blood 
sampling should be recorded .  The actual date and time (24-hour clock time )of each sampling 
will be recorded.   LY2951742 concentration informat ion that may/woul dunblind the study  will 
I5Q-MC-CGAH (a)Clinical Protocol Page 38
LY2951742 Approved: 22 January 2016not be reported to invest igative sites or blinded personnel until the study has been unblinded .  
Bioanaly tical samples collected to m easure invest igational product concentration will be retained 
for a maximum of 1 year following last patient visit for the study .
A validated assay will be used to determine serum LY 2951742 concentrations.  Samples will be 
analyzed at a laboratory  approved by  the sponsor.
It is intended that blood samples co llected fro m patients who recei ved pl acebo shoul d not be 
analyzed for determinat ion of serum concentrations of LY 2951742.
8.6. Pharmacodynamics
At the visit s and t imes specified in the Schedule of Act ivities (Appendix 2 ), venous bl ood 
samples will be co llected to determine the plasma concentrations of CGRP.  A maximum o f 3 
samples may  be collected at addit ional time po ints during the study  if warranted and agreed upon 
between both the investigator and sponsor.  Instructions for the collect ion and handling of blood 
samples will be provided by  the sponsor.  When a blood sample is collected , the time and date of 
last dose administration prior to blood sampling should be recorded .  The actual date and time 
(24-hour clock time )ofeach sampling will be recorded.
A validated LY2951742 -tolerant assay will be used to determine plasma CGRP concentrations.  
Samples will  be analyzed at a l aboratory  approved by  the sponsor.
Plasma CGRP concentration informat ion that m ay/woul d unblind the study  will not be reported 
to invest igative sites or blinded personnel unt il the study has been unblinded.
Bioanaly tical samples collected to m easure CGRP will be ident ified by the patient number 
(coded) and retained for a maximum o f 1 year following last patient visit for the study at a 
facilit y selected by  the sponsor.
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 39
LY2951742 Approved: 22 January 20168.8. Biomarke rs
Blood samples for non -genet ic biomarker research will be co llected at the times specified in the 
Schedule of Act ivities (Appendix 2 ),where local regul ations and ERBs allow.
Samples will  be used for research on the drug target, disease process, pathways associated with 
migraine headache and/or other pain condit ions, mechanism  of action of LY2951742, and/or 
research method or in validat ing diagnost ic tools or assay (s) related to mi graine headache and/or 
other pain condit ions.
All biomarker samples will be coded with the patient number.  These samples and any  data 
generated can be linked back to the patient only by the investigator site personnel.  Sa mples will 
be destroy ed according to a process consistent with local regulat ions.
Samples will  be retained for a m aximum  15 years after the l ast pati ent vi sit for the study , or f or a 
shorter period if local regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
the sponsor.   This retent ion peri od enables use o f new techno logies, response to regulatory  
questions, and invest igation of variable response that may not be observed unt il later in drug 
development or when the drug is commerciall y available.
8.8.1. Samples for Immunogenicity Research
Where local regulat ions and ERBs allow, blood samples for immunogenicit y testing will be 
collected to determine ant ibody  producti on against LY2951742 as specified in the Schedule of 
Activities (Appendix 2 ).Immunogenicit y will be assessed by a validated assay designed to 
detect anti -drug ant ibodies in the presence o f the investigational product.  Ant ibodies may be 
further characterized and/or evaluated for their abilit y to neutralize the activit y of LY2951742.
Samples will  be retained for a m aximum  of 15 y ears after the last patient visit for the study , or 
for a shorter peri od if regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
the sponsor.  The duration allows the sponsor to respond to future regulatory  requests rela ted to 
LY2951742.
8.9. Health Economics
Health economic, di sabili ty and qualit y of life assessments of LY2951742 in patients with 
migraine will be based on the fo llowing scales:
Migraine Disability Assessment test (M IDAS ): The MIDAS was designed to quantify 
headache-related di sabili ty over a 3 -month peri od.  Thi s instrum ent consists of five items that 
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 40
LY2951742 Approved: 22 January 2016reflect the number of days reported as missing, or with reduced productivit y at work or hom e and 
social events ; a higher value is indicat ive of more disabilit y (Stewart 1999 ;Stewart 2001 ).  This 
instrum ent is considered highly  reliable and valid; and is correlated with clinical judgment 
regarding the need for medical care (Stewart 1999 ;Stewart 2001) .
Migraine Specific Quality of Life questionnaire (MSQ v2.1): The MSQ v2.1 i s a self-
administered healt h status instrument, and was developed to address physical and emotional 
limitations of specific concern to individuals suffering fro m migraine headaches. The instrument 
consists of 14 items that address 3 dom ains:  (1) Rol e Functi on-Restrictive ;(2) Rol eFuncti on-
Preventive; and, (3) Emotional Funct ion (Jhingran 1998) .  The instrument was designed with a 4 -
week recall period, and is considered reliable, valid and sensit ive to change in migraine ( Jhingran 
1998; Rendas -Baum 2013 ). Clinically meaningful differences for each domain have been 
established and are widely used in the literature.
I5Q-MC-CGAH (a)Clinical Protocol Page 41
LY2951742 Approved: 22 January 20169.Statistical Considerations and Data A nalysis
9.1. Determination of Sample Size
The study  will enroll approximately 825 patients. Eligible pat ients will be randomized in 
blinded fashio nin a 2:1:1 ratio to placebo (target of 413 pat ients), LY2951742 120 mg/mo nth 
(target of 206 patients), or 240 mg/mo nth (target of 206 pat ients).  With the assumpt ion of a 26% 
discontinuat ion rate and an effect size o f 0.33, it is estimated that this sample size will provi de 
approximately  95% power that at l east 1 dose of LY2951742 will separate from placebo at a 
two-sided significance level of 0.05 based on simulat ions using Dunnett (Dunnett 1955) test.
Assumpt ions in the simulat ions w erebased on data from two double -blind ,placebo -controlled , 
Phase 2 studies, with adjust ment to reflect the longer treatment duration and greater variabilit y 
expected in a larger, mult i-country  Phase 3 study .
Approximately 100 sites in 11 countri es are pl anned for inclusio n in Study CGAH, with an 
average o f approximately  8 pat ients to be rando mized at each invest igative site.  The final 
number of sites, countries, and patients per site may vary depending on sites’ enr ollment rates .
Approximately 1557 pat ients may be screened to ensure randomizat ion of 825 patients, with an 
estimated 611 patients completing the study .
9.2. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Lillyor its desi gnee.   Details o f 
statist ical analysis methods will be described in the statist ical analysis plan (SAP) document.
Unless otherwise specified, analyses will be conducted on an intent -to-treat (ITT) populat ion, 
which will include all pat ients who are randomized and receive at least one dose of 
investigat ional product.  Patients in the ITT population will be analyzed according to the 
treatm ent group to whi ch they  are randomized. When change fro m baseline is assessed, the 
patient will be included in the analysis only if he/she has a baseline and a postbaseline 
measurement.
The primary  analys is will be performed using a restricted maximum likelihood -based mixed 
models repeated m easures (MMRM) technique with prespecified model terms (Secti on 9.4.1 ).
Visitwise binary efficacy  variables will be analyzed using a generalized linear mixed model 
(GLIMMIX) as pseudo -likelihood -based mixed effe cts repeated measures analysis .
In addit ion to the MMRM approach, analysis o f covariance (ANCOVA) model or analysis of 
variance (ANOVA) with the l ast observat ion carried forward (LOCF) will also be implemented. 
When an ANCOVA model is used to analyze a con tinuous variable, the model will contain the 
main effects of treatment and region, as well as the conti nuous fixed covariates of baseline.   The 
ANOVA model will use the same terms except the continuous fixed covariate of baseline.  
TypeIII sum -of-squares for the l east-squares means will be used for the statist ical co mpar isons.
Continuous efficacy and health outcome endpo ints will be analyzed using MMRM methods, as 
well as an ANCOVA model wit h LOCF imputation if deemed appropriate .
I5Q-MC-CGAH (a)Clinical Protocol Page 42
LY2951742 Approved: 22 January 2016Categorical co mpar isons b etween treatm ent groups will be performed using Cochran -Mantel -
Haenszel (CMH) controlling for region orusing the Fisher’s exact test, where appropriate.
Patients will be pooled within each regi onfor statisti cal analysis purposes.   Region will be 
defined in the SAP.
All tests of treatment effects will be conducted at a 2-sided al pha level of 0.05, unless otherwise 
stated.
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol.  Any  other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the clinical study  report or SAP .  Changes may only be made in the SAP prior to unblinding .  
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.
9.3. Treatment Group Comparability
9.3.1. Patient Disposition
The number and percentage of ITT patients who complete the study or discontinue early will be 
summariz ed for all treatm ent groups for Study  Period III (double -blind treatment) and Study  
Period IV (post -treatm ent follow-up) both overall and by visit .
Patient allocation by  invest igator will be summarized for Study Period III for all ITT patients. 
Patient allocat ion by invest igator will also be listed for all study periods.
9.3.2. Patient Characteristics
The fo llowing pati ent characteri stics at baseline will be summarized by  treatm entgroup for all 
ITT patients :
Dem ographic (age, gender, ethnic origin, height, weight, body mass index )
Migraine headache, headache, variation of migraine/headache measures per 30 -
day baseline period.
Alcoho l,tobacco , caffeine and nicotine consumption
Medical history  and pre -exist ing condit ion
Medical history and pre -exist ing condit ions will be summarized by preferred term within system  
organ class (SOC) .
9.3.3. Concomitant Therapy
The proporti on of  patients who received conco mitant medicat ion (as recorded via eCRF) as well 
as abortive medicat ions (recorded through ePRO) will be summarized for all ITT patients for 
Study  Period III and Study  Period IV separately.
9.3.4. Treatment Compliance
Not applicable.
I5Q - MC- CGAH(a )C l in ica lP ro toco l Page  43
LY2951742 App roved :  22  Janua ry  20169 .3 .5 .E lec t ron ic  Pa t ien t- repo r ted  Ou tcomeD ia ryComp l iance
ePRO  d i a ry  com p l i a n c e  a t  e a c h  p e r i o d  ( i n c l u d i n g  b a s e l i n e ,  M o n t h  1 ,  2 ,  3 ,  …  t i l l  M o n t h  1 0 )  w i l l  
b ec a l cu l a t ed .   D i a ry  com p l i a n c e  a t  e a c h  p e r i o d  i s  c a l cu l a t ed  a s :
A c tu a l	 numb e r	 o f	 d i a ry	 d ay s	 in 	 th e 	 p e r iod
E xp e c t ed	 numb e r	 o f	 d i a ry	 d ay s	 in 	 th e 	 p e r iod∗100
A c tu a l n umb e r  o f  d i a ry  d a y s  i s  c a l c u l a t e d  a s  t h e  t o t a l  n um b e r  o f  d a y s  w i t h  n o n- m i s s i n g  a n sw e r s.
9 .4 .P r imary  and  Seconda r y  Ana lyses
9 .4 .1 .P r ima ry  Ana lyses
Th e  p r im a ry e f f i c a cy  m e a su r e  i s  th e  o v e r a l l  m e a n  c h a n g e  f r om  th e  b a s e l i n e  p e r i o d  i n  t h en um b e r  
o fm on th ly  m i g r a i n e  h e a d a c h e  d a yd u r i n g  th e  6 - mon thd o u b l e- b l i n dt r e a tm e n t  p h a s e ,  and  t h e  
p r im a ry  a n a l y s i s  w i l l  e v a l u a t e  t h e  e f f i c a c y  o f  LY 2 9 5 1 7 4 2( 1 2 0  o r  2 4 0  m g /m o n th )  com p a r ed  w i th  
p l a c e b o .
Th e  p r im a ry an a ly s i s  w i l l  b e  p e r f o rm e d  u s i n g  a  r e s t r i c t e d  m a x im um  l i k e l i h o o d - b a s e d  MMRM  
t e c h n i q u e .   T h e  a n a l y s i s  w i l l  i n c l u d e  t h e  f i x e d  c a t e g o r i c a l  e f f e c t s  o f  t r e a tm e n t ,  r e g i o n ,  m on th ,  
a n d  t r e a tm e n t -b y - m on th  i n t e r a c t i o n ,  a s  w e l l  a s  th e  c o n t i n u o u s  f i x e d  c o v a r i a t e s  o f  b a s e l i n e  
n um b e r  o f  m i g r a i n e  h e a d a c h e  d a y s  a n d  b a s e l i n e  n um b e r  o f  m i g r a i n e  h e a d a c h e  d a y s -b y - m on th
i n t e r a c t i o n .
A n  u n s t r u c t u r e d  c o v a r i a n c e  s t r u c t u r e  w i l l  b e  u s e d  t o  m od e l  w i th i n - p a t i en t  e r ro r s .   T h e  K e nw a r d-
R o g e r  (K e nw a r d  a n d  R o g e r  1 9 9 7 )  a p p r o x im a ti o n  w i l l  b e  u s e d  t o  e s t im a t e  d e n om i n a t o r  d e g r e e s  
o f  f r e e d o m . I f  t h e  m o d e l  d o e s  n o t  c o n v e r g e  w i t h  b o t h  t h e  H e s s i a n  a n d  t h e  G  m a t r i x  b e i n g  
po s i t i v e  d e f in i t e  und e r  th e  d e f au l t  fi t t ing  a lgo r i thm  u s ed  by  PROC  M IXED ,  t h e  F i s h e r  s c o r i n g  
a l go r i thm  w i l l  b e  imp l em en t ed  by  sp e c i fy ing  th e  SCOR ING  op t ion  in  SAS .  I f  t h e  m o d e l  s t i l l  
f a i l s  t o  c o n v e r g e ,  t h e  m o d e l  w i l l  b e  f i t  u s i n g  c o v a r i a n c e  m a t r i c e s  o f  th e  f o l l o w i n g  o r d e r  s p e c i f i e d  
b y  a  d e c r e a s i n g  n um b e r  o f  c o v a r i a n c e  p a r am e t e r s  u n t i l  c o n v e r g e n c e  i s  m e t :
• H e t e r o g e n e o u s  T o e p l i t z
• H e t e r o g e n e o u s  F i r s t- o r d e r  a u t o r e g r e s s i v e
• T o e p l i t z
• F i r s t - o r d e r  a u t o r e g r e s s i v e
W h e n  t h e  u n s t r u c t u r e d  c o v a r i a n c e  m a t r i x  i s  n o t  u t i l i z e d ,  t h e  s a n dw i c h  e s t im a t o r  (D i g g l e  a n d
K e nw a r d  1 9 9 4 )  w i l l  b e  u s e d  t o  e s t im a t e  t h e  s t a n d a r d  e r r o r s  o f  t h e  f i x e d  e f f e c t s  p a r am e t e r s .   T h e  
s a n dw i c h  e s t im a t o r  i s  im p l em e n t e d  b y  s p e c i f y i n g  t h e  EMP IR ICAL  o p t i o n  i n  SAS®.   Wh en  th e  
s a n dw i c h  e s t im a t o r  i s  u t i l i z e d ,  t h e  K e nw a r d - R o g e r  a p p r o x im a ti o n  f o r  d e n om i n a t o r  d e g r e e s  o f  
f r e e d o m  c a n n o t  b e  u s e d .   I n s t e a d ,  t h e  d e n o m i n a t o r  d e g r e e s  o f  f r e e d om  w i l l  b e  p a r t i ti o n ed  in to  
b e tw e en - s u b j e c t  a n d  w i t h i n - sub j e c t  po r t ion s  by  t h e  DDFM=BETW ITH IN  o p t i o n  i n  SAS®.   
SAS®PROC  M IXED  w i l l  b e  u s e d  t o  p e r f o rm  t h e  a n a l y s i s .
I5Q-MC-CGAH (a)Clinical Protocol Page 44
LY2951742 Approved: 22 January 20169.4.2. Key Secondary Analyses
The key  secondary  object ives (see Table CGA H.1) will be tested using an appropriate mult iple 
testing approach providing strong control  of the familywise error rate (for the primary and key  
secondary  tests) at a one -sided 0.025 alpha level (or, equivalent ly, two -sided 0.05 alpha level) .
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 45
LY2951742 Approved: 22 January 2016There will be no adjust ments for m ultiplicity for analyses of other endpoints.  If themultiple 
testing approach for key  secondary  measures only  needsto be changed, the updated approach 
will be provided in the SAP,and it shoul d not lead to modification of this protocol .
The key  secondary  measures will be analyzed for the double -blind treatment ( Study PeriodIII).
For the conti nuous key secondary  measures, the change fro m baseline during the 6 -month 
doubl e-blind treatment phase will be analyzed from repeated measures analyses as described in 
Secti on 9.4.1 .
  Forthe analysis o f 50%, 75%, and 100% response, the percentage of patients 
meet ing response criteria during the 6 -month double -blind treatment phase will be est imated for 
each treatment fro m a categori cal, pseudo -likeliho od-based repeated measures analysis of 
longitudinal binar y outcom es indicating whether patients meet response criteria .
This analysis will be implemented using the GLIMMIX procedure in SAS .
9.4.3. Other Secondary and Tertiary Efficacy Analyses
The other secondary  and exploratory  efficacy analyses will be conducted for the doubl e-blind 
treatm ent phase, and for the double -blind treatment and post -treatm ent follow-up phases ( Study 
Period III and Study Period IV)combined.   Further details regarding other secondary and tertiary 
efficacy analyses are summarized in the SAP.
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 46
LY2951742 Approved: 22 January 20169.5. Safety Analyses
The safet y analys es will  be conducted for the double- blind treatment and post -treatm ent follow-
up phases, as well as the two periods combined.  For the two phases combined, only repeated 
measures and time -to-event analys es will  be conducted.
The safet y and tol erabilit y of treatm ent will be assessed by  summarizing the following:
adverse events
otreatm ent-emergent adverse events ( TEAEs )
by preferred term
by SOC
by maximum severit y
by outcom e
considered to be related to investigat ional product by invest igator
oserious adverse event
oadverse event leading to discont inuat ion
Suicidal  ideati on and behavi ors assessed by solicit ed questioning using the C -
SSRS
Vital signs and weight
electrocardi ogram s
Laboratory  measurements
Anti-LY2951742 ant ibody
9.5.1. Catego rical Safety Variables
Unless specified otherwise, the categorical safet y analyses will include both schedule and 
unscheduled visits .
Com parisons between treatment groups for all categorical safet y measures will be made using 
the Fisher ’sexact test for S tudy Period III (double -blind treatment) withtheITT populat ion.  
Descript ive statistics only will be presented for the treatment groups in the post -treatm ent 
follow-up phase ( Study Period IV)with the post-treatment populat ion.
9.5.2. Adverse Events
Treatment -emergent adverse events are defined as the reported AEs that first occurred or 
worsened during the postbaseline phase co mpared with baseline phase.  For each TEAE, the 
severit y level o f the event (mild, moderate, or severe) will be determined by patient or physician 
opinio n.  The Medi cal Dict ionary for Regul atory  Activities(MedDRA ) Lowest Level Term will 
be used in the treatment -emergent computation.  For each Lowest Level Term , the m aximum  
severit y at baseline will be used as the baseline severi ty.  If the maximum severit y during 
I5Q-MC-CGAH (a)Clinical Protocol Page 47
LY2951742 Approved: 22 January 2016postbaseline is greater than the maximum baseline severit y, the event is considered to be 
treatm ent-emergent for the specific postbaseline period.  For each patient and TEAE, the 
maximum severit y for the MedDRA l evel bei ng displayed ( PT, High Level Term, or SOC )is the 
maximum postbaseline severit y observed fro m all associ ated L owest Level Terms mapping to 
that MedDRA level.
For events that are gender -specific, the deno minator and computation of the percentage will 
includ e only  patients from the given gender.
9.5.3. Suicide -Related Thoughts and Behaviors
Suicidal  ideati on, suicidal  behavi or, and non -suicidal  self-injuri ous behavi orbased on the 
C-SSRS will be summarized by treatment group.  For each of the fo llowing events, the n umber 
and percentage of patients with the event will be enumerated by  treatm ent:  com pleted sui cide, 
non-fatal suicide attem pt, interrupted attempt, aborted attempt, preparatory  acts or behavior, 
active suicidal ideat ion with specific plan and intent, acti ve suicidal ideat ion with som e intent to 
act wi thout specific plan, active suicidal ideat ion with any methods (not pl an) wi thout intent to 
act, non -specific act ive suicidal thoughts, wish to be dead, and non -suicidal self -injuri ous 
behavior.   In addition, the number and percentage of patients w ho experienced at least one of the
composite measures during Study  Period III and Study  Period IV separately will be presented
and co mpared .  These include suicidal acts (completed suicide and nonfatal suicidal attemp ts), 
suicidal behavi or (suici dal acts, interrupted attem pts, aborted attem pts, and preparatory  acts or 
behavior), treatment -emergent sui cidal  ideati on or treatm ent-emergent suicidal behavior.
The Fisher’s exact test will be used for treatment comparisons.
9.5.4. Vital Signs and Weight
Vital signs collected during the study  include systolic and diastolic blood pressure, pulse, and 
temperature.  Bl ood pressure and pul se measurements will be taken when the pat ient is in a 
sitting posi tion. Three measurements of sitt ing blo od pressure and pulse will be collected at 
every visit ; the 3 sitting blood pressure and pulse measurements will be averaged and used as the 
value for that visit for analysis .
The incidence rates of patients with treatment -emergent vi tal sign and we ight changes based at 
any time postbaseline and at LOCF endpo int will be assessed using the Fisher’s exact test.  
Specific criteria for treatment emergent definit ion will be documented in the SAP.
9.5.5. Electrocardiogram Intervals and Heart Rate
Analyses of corrected QT interval will be calculated using two correction formulas.  The QTcF 
(measured in milliseconds [msec]) will be calculated with Fridericia’s formula as QT/RR⅓.  The 
Large Clinical Trial Populat ion Based QT Correction (QTcLCTPB) (msec) will be c alculated 
with the f ormula as QT/RR0.413.  The number and percent of patients meet ing criteria for 
treatm ent-emergent abnormalit ies in ECG intervals ( pulse rate [ PR], QRS, QTcF, and 
QTcLCTPB) and heart rate at any  time during study  will be summarized.  Tre atment group 
comparisons will be performed using the Fisher’s exact test.
I5Q-MC-CGAH (a)Clinical Protocol Page 48
LY2951742 Approved: 22 January 20169.5.6. Laboratory Tests
The incidence rates of patients with treatment -emergent abnormal, high, or l ow laboratory  values 
at any  time postbaseline and at LOCF endpo int will be assessed using the Fisher’s exact test for 
each l aboratory  test.
Patients will  be defined as having a treatment -emergent l ow value if they  have all  normal or high 
values at baseline, fo llowed by  a value bel ow the lower reference limit at any  postbaseline visit.  
Patients with all norm al or hi gh values at baseline (no low values) will be included in the 
analysis of treatment -emergent low laboratory  values.  Patients will be defined as having a 
treatm ent-emergent high value if they have all normal or low values at baseline , followed by  a 
value above the upper reference limit at any  postbaseline visit.  Pati ents wi th all normal or low 
values at baseline (no high values) will be included in the analysis o f treatm ent-emergent hi gh 
laboratory  values.
For analytes simply classif ied as norm al or abnormal , pati ents will  be defined as having a 
treatm ent-emergent abnormal value if they have all normal values at baseline, fo llowed by an 
abnorm al value at any  postbaseline visit.  Patients with all normal values at baseline will be 
included in the analysis o f treatm ent-emergent abnorm al laboratory  values.
9.7. Other Analyses
9.7.1. Health Economic s
The change from baseline to each postbaseline visit for the doubl e-blind treatm ent phase and for 
the double -blind treatment and post -treatm ent follow-up phases combined for MSQ v2.1(Role 
Funct ion-Restri ctive, Role Funct ion-Prevent ive, Emotional Function,andtotal score )and
MIDAS (item scores and total  score )will be analyzed.  In addit ion, categorical analysis for the 
frequency  measure will be performed .
9.7.2. Subgroup Analyses
Subgroup analyses will be performed for the primary efficacy measure (change fro m baseline in 
the number of migraine headache days) separately  for each of the subgroup populat ions listed in 
Table CGA H.4.  Subgroup analyses will be conducted only for the ITT patients in Study  Period 
III.
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 49
LY2951742 Approved: 22 January 2016Each of t he subgroup analyses for the primary measure of change fro m baseline in the numbe r of 
migraine headache days will be conducted using MMRM. The same MMRM model described 
in Section 9.4.1 will be used ,with term s of subgroup, subgroup -by-treatm ent, subgroup -by-
month, and subgroup -by-treatm ent-by-month interacti ons added as addi tional co variates.
Table CGAH.4. Definition of Subgroup Variables
Subgroup Variable Categories
Sex Male, female
Racial Origin (combine those with 
less than 10%)American Indian / Alaskan Native
Asian
Black / African American
Native Hawaiian / Pacific Islander
White
Multiple
Ethnicity Hispanic o r Latino
Not Hispanic or Latino
Region Defined in the statistical analysis plan ( SAP)
Baseline number of migraine 
headache days2levels of baseline migraine frequency :
<8 migraine headache days
≥8 migraine headache days
Treatment -resistant status Treatment -resistant status about whether a patient has failed 2 or 
more prophylactic treatments (Yes or No)
Having aura or not (during baseline 
period)Yes or No
Baseline a nti-drug antibody status Any confirmed positive anti-drug antibody at baseline (Yes 
versus No)
Neutralizing anti-drug antibody
statusAny positive neutralizing anti-drug antibody time point (Yes 
versus No) –note that neutralizing ADA assays are performed 
only on confirmed -positive anti-drug antibod ies .
Treatment -emergent anti-drug 
antibody statusAny treatment -emergent anti-drug antibody (Yes v ersus No)
9.8. Interim Analyses
Two interim analyses are antici pated for this study.  The first possible interim analysis will occur 
during Study  Period III (doubl e-blind treatment) and could result in stopping the trial for safety 
or fut ility.  This analysis is planned to occur when approximately 330 (40% o f the total sample 
size) rando mized pati ents have had the chance to complete at least 3 months of the treatment 
period.  The interim analysis will be conducted by  an independent data monitoring committee 
(DMC) wi th members external to Lilly .  The data from the interim analysis will be used to 
evaluate whether to stop or modify the study  for futility and/or safet y issues.  Stopping rules for 
futilit y at thi s interim analysis will be based on the conditional power of comparing LY2951742 
to placebo.  Specifica lly, condi tional power represents the probabilit y that the ongoing trial will 
I5Q-MC-CGAH (a)Clinical Protocol Page 50
LY2951742 Approved: 22 January 2016resul t in a stati stically significant difference between LY2951742 and placebo at end of the trial, 
based on the data available at the time of the interim analysis.  Rules for st opping the study  are 
detailed in the Statist ical Analysis Cent er SAP and the DMC Charter.   Only the DMC is 
authori zed to eval uate unblinded interim efficacy and safet y analyses.   Study  sites will  receive 
inform ation about interim results ONLY if they need to know for the safet y of their pati ents.  
There i s no inflat ion of ty pe 1 error due to the conduct of a fut ility analysis (Snapinn et al. 2006), 
so no adj ustment to the nominal significance level will be made forthe primary  analysis as a 
resul t ofa futility assessment .
The second interim analysis will be conducted after all pat ients have had the opportunit y to 
complete Study  Period III, and thus, will be the final analysis of the primary efficacy  endpoint .
Unblinding details are specified in the unblinding pl an sect ion of the SAP or a separate 
unblinding plan document .
Addit ional interim analyses m ay be conducted in support of regulatory  submissio ns if necessary .
I5Q-MC-CGAH (a)Clinical Protocol Page 51
LY2951742 Approved: 22 January 201610.Study  Governance Considerations
10.1. Regulatory and Ethical Considerations, Including the Informed 
Consent Process
10.1.1. Informed Consen t
The invest igator is responsible for ensuring:
that the patientunderstands the potential risks and benefits of part icipating in the 
study
that informed consent is given by each patient.  This includes obtaining the
appropriate signatures and dates on the ICF prior to the performance of any 
protocol  procedures and prior to the administration of invest igational product.
answering any quest ions the pati entmay have throughout the study  and sharing in 
a timely manner an y new informat ion that m ay be rel evant to the patient’s
willingness to continue his or her participat ion in the trial.
10.1.2. Ethical Review
The invest igator must give assurance that the ERB was properly const ituted and convened as 
requi red by Internat ional Conference on Harmonisation (ICH) guidelines and other applicable 
laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representativ es must approve the ICF, 
including any  changes made by the ERBs, before it is used at the invest igative site(s).  All ICFs
must be compliant with the ICH guideline on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and up dates during the course of the study
inform ed consent docum ent
relevant curri cula vi tae
10.1.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council forInternational Organizati onsof
Medical Sciences (CIOMS ) Internati onal Ethi cal Gui delines
applicable ICH GCP guidelines
applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third-party organi zation (TPO) .
I5Q-MC-CGAH (a)Clinical Protocol Page 52
LY2951742 Approved: 22 January 201610.1.4. Investigator Information
Invest igators in this clinical trial should be neuro logists, headache specialists, or other specialists 
with experi ence in headache clinical trials and treating migraine headache pat ients.
10.1.5. Protocol S ignatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal i nvest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
10.1.6. Final Report Signature
The clinical study  report ( CSR )coordinating investigator will sign the final CSR for this study , 
indicat ing agreement that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
An invest igator selected by  the study  team  will serve as the CSR coordinat ing invest igator.  If 
this inve stigator is unable to fulfill this funct ion, another invest igator will be chosen by Lilly to 
serve as the CSR coordi nating invest igator.
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
10.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal mat erial to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instructi on on the protocol, the complet ion of the eCRFs, and 
study  procedures .
make periodic visit s to the st udy site
be available for consultation and stay  in contact with the study  site personnel by  
mail/e-mail, telephone, and/or fax
review and evaluate eCRF data and use standard computer edits to detect errors in 
data collect ion
conduct a qualit y review of the database
In addit ion, Lilly or its representatives willperiodically check a sample of the patient data
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly or i ts 
representatives ,and/or by regul atory  agencies at any  time.  Invest igators will be given notice 
before an audit occurs.
I5Q-MC-CGAH (a)Clinical Protocol Page 53
LY2951742 Approved: 22 January 2016To ensure the safet y of parti cipants in the study , and to ensure accurate, complete, and reliable
data, the invest igator will keep records of ECGs, laboratory tests, clinical notes, and patien t
medical records in the patient files as original source documents for the study  according to 
retenti on requi rements as outlined by the ICH guidelines .  If requested, the investigator will 
provi de the sponsor, applicable regulatory  agencies, and applicabl e ERBs wi th direct access to 
original  source docum ents.
10.2.1. Data Capture System
An electronic data capture sy stem will be used in this study .  The si te maintains a separate source 
for the data entered by  the si te into the sponsor -provided electronic data captu re system .
Some or all  of a patient’s data will be direct ly entered into the eCRF at the time the i nformation 
is obtained. In instances where direct data ent ry is not used, the site will maintain source 
docum entati on in the tri al files ,and the patient’s data will  be transcribed into the eCRF .  Any 
data for whi ch the eCRF will serve as the source document, or any  other data not entered direct ly 
into the eCRF, will be identified and documented by  the si te in the si te’s trial  file. For data 
handled by  a dat a management TPO, eCRF data and some or all data that are related will be 
managed and stored electronically in the TPO system .  Subsequent to the final database lock, 
validated data will be transferred to the sponsor. For data handled internally, eCRF dat a and 
some or all data that are related will be managed by the sponsor and stored electronically in the 
sponsor ’s system .
In thi s study , pati ent migraine headache data will be collected directly via an ePRO diary  as part 
of an ePRO/Clinical Outcome Assessm ent (COA) system . Patient -rated scales/quest ionnaires 
will be co llected direct ly via an ePRO tablet device at each visit .  Data entered into the 
ePRO/COA system will serve as the source data.
If ePRO/COA records are stored at a third -party  site, investiga tor si tes will  have continuous 
access to the source documents during the study  and will receive an archival copy  at the end of 
the study  for retenti on.
Any data for which the ePRO/COA instrument record will serve to collect source data will be 
ident ified a nd docum ented by  each si te in that si te’s study  file.
Case report form data will be encoded and stored in a clinical trial database.  Data managed by a 
central  vendor, such as laboratory  test data or ECG data, will be stored electronically in the 
central  vendor’s database system.  Data will subsequent ly be transferred from the central vendor 
to the Lilly data warehouse . Data from compla int forms submitted to Lilly will be encoded and 
stored in the global product complaint management sy stem.
I5Q-MC-CGAH (a)Clinical Protocol Page 54
LY2951742 Approved: 22 January 201610.3. Study and Site Closure
10.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , theinvest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
10.3.2. Discontinuation of the Study
The study  will be discontinued if Lilly or its designee judges it necessary  for medical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
I5Q-MC-CGAH (a)Clinical Protocol Page 55
LY2951742 Approved: 22 January 201611.References
Diggle P, Kenward MG. Informative drop -out in longi tudinal  data analysis. J Royal Statist Soc 
Series C: Appl Statist . 1994;43(1):49 -93.
Goadsby  PJ, Edvinsson L. The tri gemino vascular sy stem and migraine: Studies characterizing 
cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol . 
1993;33(1):48 -56.
Goadsby  PJ, Edvinsson L, Ekm an R. Vasoactive peptide release in the extracerebral circulat ion 
of humans during migrain e headache. Ann Neurol . 1990;28(2):183 -187.
Guy W. ECDEU assessment manual for psychopharmacology , revised 1976. Rockville, MD: 
National Inst itute of Mental Health, Psychopharmacology  Research Branch. p 217 -222. 
Available at: https://archive.org/details/ecdeuassessmentm1933guyw. Accessed January 11,
2016.
[ICHD -3] Headache Classificat ion Co mmittee of the Internat ional Headache Societ y (IHS). The 
International Classificat ion of Headache Disorders, 3rd edit ion (beta versio n). Cephalalgia . 
2013;33(9):629 -808.
Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoetfer L. Development and validat ion of 
themigraine -specific qualit y-of-life quest ionnaire. Headache .1998;38(4):295 -302.
Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum 
likelihood. Biometrics . 1997;53 (3):983-997.
Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a 
causat ive role in migraine. Cephalalgia .2002;22(1):54 -61.
Lassen LH, Jacobsen VB, Pedersen PA, Sperling B, Iversen H, Olesen J. Human calcitonin gene -
related pepti de (hCGRP)- induced headache in migraineurs. Eur J Neurol . 
1998;5(suppl 3):S63.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin 
GA, Greenhill L, Shen S, Mann JJ. The Co lumbia -Suicide Severi ty Rating Scale: init ial 
CCI
CCI
CCI
CCI
CCI
I5Q - MC- CGAH(a )C l in ica lP ro toco l Page  56
LY2951742 App roved :  22  Janua ry  2016v a l i d i ty  and  in t e rn a l  c o n s i s t e n c y  f i n d i n g s  f r om  t h r e e  m u l t i s i t e  s t u d i e s  w i t h  a d o l e s c e n t s  a n d  
adu l t s .Am  J  P s y c h i a t r y.  2011 ;168 (12 ) :1266 -1 27 7 .
R e n d a s- B aumR ,  B loud ek  LM ,  M ag l in t e  GA ,  V a ron  SF .  Th e  p syc h o m e tr i c  p rop e r t i e s  o f  t h e  
M ig r a in e- S p e c i f i c  Q u a l i tyo f  L i f e  Q u e s t i o n n a i r e  v e rs i o n  2 . 1  (MSQ )  i n  c h r o n i c  m i g r a i n e
p a t i en t s.  Qua l  L i f e  R e s.2 0 1 3 ; 2 2(5 ) :1123 –1 1 3 3 .
R iz zo l i  P .  P r ev en t iv e  ph a rm a co th e r apy  i n  m i g r a i n e .  H e a d a c h e.  2014 ;54 (2 ) :364 - 3 6 9 .
S il b e r s t e i n  SD ,  H o l l a n d  S ,  F r e i t a g  F ,  D o d i c k  DW ,  A r g o f f  C ,  A s hm a n  E .  E v i d e n c e - b a s e d  
gu i d e l i n e  u p d a t e :  P h a rm a c ol o g i c  t r e a tm en t  f o r  ep i sod i c  m i g r a i n e  p r e v e n t i o n  i n  a d u l t s :  R e p o r t  
o f  t h e  Q u a l i t y  S t and a rd s  Sub comm i t t e e  o f  th e  Am e r i c an  A c ad emy  o f  N eu ro logy a n d  th e  
Am e r i c a n  H e a d a c h e  S o c i e ty .  N e u r o l o g y.  2012 ;78 (17 ) :1337 -1 3 4 5 .
S n a p i n n  S ,  C h e n  MG ,  J i a n g  Q ,  K o u t s o u k o s  T .  A s s e s sm e n t  o f  f u ti l i t y  i n  c l i n i c a l  t r i a l s .  P h a rm  
S ta t.2 0 0 6 ; 5 ( 4 ):2 7 3–2 8 1 .
S t ew a r t  WF ,  L i p t o n  RB ,  D ow s o n  A J ,  S aw y e r  J .  D e v e l o pm e n t  a n d  t e s t i n g  o f  t h eM ig r a i n e  
D is ab i l i ty  A s s e s sm e n t  (M IDAS )  Q u e s t i o n n a i r e  t o  a s s e s s  h e a d a c h e - r e l a t ed  d i s ab i l i ty  ( ab s t r a c t ) .  
N e u r o l o g y.  2 0 0 1 ; 5 6  ( 6  S u p p l  1 ): S20–S28 .
S t ew a r t  WF,  L ip ton  RB ,  Ko l odn e r  K ,  L ib e rm an  J ,  S awy e r  J .  R e l i a b i l i ty  o f  t h e  m i g r a i n e  
d i s ab i l i ty  a s s e s sm en t  s co r e  i n  a  p o p u l a t i o n- b a s e d  s am p l e  o f  h e a d a c h e  s u f f e r e r s .  C e p h a l a l g i a
1 9 9 9 ; 1 9 (2 ) :107-1 1 4 .
V i l l a l ón  CM ,  O l e s e n  J .  T h e  r o l e  o f  CGRP  i n  t h e  p a t h o p h y s i ol o gy  o f  m ig r a in e  and  e f f i c a cy  o f  
CGRP  r e c e p t o r  a n t a g o n i s t s  a s  a c u t e  a n t im i g r a i n e  d r u g s .  P h a rm a c o l  T h e r.  
2 0 0 9 ; 1 2 4 ( 3 ) : 3 0 9-3 2 3 .
V o s  T ,  F l a xm a n  AD ,  N a g h a v i  M ,  L o z a n o  R ,  M i c h a u d  C ,  E z z a t i  M ,  e t  a l .  Y e a r s  l i v e d  w i t h  
d i s ab i l i ty  (YLD s )  f o r  1 16 0  s e q u e l a e  o f  2 89  d i s e a s e s  a n d  i n j u r i e s  1 9 9 0 - 2 0 1 0 :  a  s y s t em a ti c  
a n a l y s i s  f o r  t h e  G l o b a l  B u r d e n  o f  D i s e a s e  S t u d y  2010 .  L a n c e t.2 0 1 2 ; 3 8 0 ( 9 8 5 9 ) :  2 1 6 3 -2 1 9 6 .
I5Q-MC-CGAH (a)Clinical Protocol Page 57
LY2951742 Approved: 22 January 2016Appendix 1. Abbreviations and Definitions
Term Definition
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or
not related to the medicinal (investigational) product.
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
perfo rmance of a drug or drug delivery system.
CRP/CRS Lilly  Clinical Research Physician/Clinical Research Scientist
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment.
enter Patients entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives .
ePRO electronic patient -reported outcomes
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational 
productApharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial ,including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
ITT intent to treat : The principle that asserts that the effect of a treatment policy can be best 
assessed by evaluating o n the basis of the intention to treat a patient (that is, the planned 
treatment regimen) rather than the actual tr eatment given.  It has the consequence that 
patients allocated to a treatment group should be followed up, assessed ,and analyzed as 
members of that group irrespective of their compliance to the planned course of 
treatment.
IWRS interactive web-response s ystem
SAE serious adverse event
TEAE treatment -emergent adverse event : Any untoward medical occurrence that either occurs 
or worsens at any time after treatment baseline and thatdoes not necessarily have to 
have a causal relationship with this treatment .
I5Q-MC-CGAH (a)Clinical Protocol Page 58
LY2951742 Approved: 22 January 2016Appendix 2. Schedule of A ctivities
I5Q-MC-CGAH (a)Clinical Protocol Page 59
LY2951742 Approved: 22 January 2016Schedule of Activities , Protocol I5Q-MC-CGAH
Study Period (SP)SP I-
ScreeningSP II -
Prospective 
BaselineSP III -Treatment SP IV –Follow -up
(Target) I nterval (days) 
since previous visit30-45 14 16 30 30 30 15 15 15 15 60 60
ETAllowable range (days) 
between visits3-45 30-40a
Interval allowance (days) +/- 1 +/- 3 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 5 +/- 5
Visit 1 2 3 4 b 5 6 7 8 9c10 11c12 13 14
Month 0 0.5 1 2 3 4 4.5 5 5.5 6 8 10
Assessments and Procedures
Informed consent X
Inclusion /exclusion X X X
Demographics X
Physical examination X
Neurological 
examination d X X X X X
Height X
Weight X X X X
Waist and hip 
circumference X
Medical history X
Pre-specified 
migraine historyX
I5Q-MC-CGAH (a)Clinical Protocol Page 60
LY2951742 Approved: 22 January 2016Visit 1 2 3 4b5 6 7 8 9c10 11c12 13 14ET
Month 0 0.5 1 2 3 4 4.5 5 5.5 6 8 10
Substance use X
ECG e X X X X X
Vital signs f X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X
Concomitant medications X X X X X X X X X X X X
ePRO training X
ePRO daily patient entries X X X X X X X X X X X X X X
Patient training video X
Clinical Laboratory Tests and Sampling Schedules
Hematology X X X X X X
Clinical chemistry X Xg Xg Xg Xg Xg
HDL X Xg Xg Xg Xg Xg
HbA1c X X X X
Fasting insulin/
fasting C -peptideXgXgXg
UrinalysishX X X X X
Serum Pregnancy (for 
women of childbearing 
potential) or FSH at Visit 
1 (all other female 
patients) iX X X X
Urine pregnancy i X X X X X X
Urine drug screen X
I5Q-MC-CGAH (a)Clinical Protocol Page 61
LY2951742 Approved: 22 January 2016Visit 1 2 3 4b5 6 7 8 9c10 11c12 13 14ET
Month 0 0.5 1 2 3 4 4.5 5 5.5 6 8 10
ImmunogenicityjX X X X X X X X
Biomarker storage samplejX X X X X X X X
PK blood samplejX X X X X X X X X X X X
RNA X X X
Study drug administeredkX X X X X X
Scales, Questionnaires, and Outcome Measures
MIDAS X X X X X
MSQ v2.1 X X X X X X X X X
Non-migraine chronic 
pain assessmentlX X X X
PGI-S X X X X X X X X X
PGI-I X X X X X X X
C-SSRS/SHSF, SHFU m X X X X X X X X X X X X
Abbreviations:  AE = adverse event; CGRP = Calcitonin -gene related peptide; C-SSRS = Columbia -Suicide Severity Rating Scale ; ECG = electrocardiogram ; 
ePRO = electronic patient reported outcome s; ET = early  termination; FSH = follicle stimulating hormone; HDL = High -density  lipoprotein; MIDAS = 
Migraine Disability Assessment test; MSQ (v2.1) = Migraine Specific Quality of Life Questionnaire; PGI-I = Patient Global Impression of Improvement; 
PGI-S = Patient Global Impression of Severity; PK = pharmacokinetics ;RNA = ribonucleic acid; SHSF = Self-harm supplement form ; SHFU = Self-harm 
follow -up form .
Note :  Selected tests may be obtained in the event of a treatment -emergent hepatic abnormality and may be required in follow -up with patients in consultation 
with t he Lilly , or its designee, clinical research physician. See A ppendix 4 for more details regarding specific hepatic monitoring tests.  If the patient has 
discontinued the trial and returns for hepatic follow -up, the site should use the 800 series as the vi sit designation.
CCI
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 62
LY2951742 Approved: 22 January 2016Schedule of Activities , Protocol I5Q-MC-CGAH (footnotes)
aThe eligibility period of the prospective baseline assessment will lastfrom 30 to 40 days .  Investigators and patients may have up to an additional 5days to 
schedule their V isit 3 appointment (beyond the 40 days); however, eligibility will be based on the 30 -40 day period.
bVisit is to include a review of any spontaneously reported adverse events and collection of blood samples for immunogenicity, PK, and CGRP plasma .
cVisit 9 and Visit 11 are laboratory visits (for PK and CGRP plasma) only. Adverse events are not intended to be collected at these visits because patients may 
be going to a different location for laboratory assessments.  However, any spontaneously report edAEs at these lab visit s should be reported on the AE page.
dA neurological exam will be conducted at screening, Month 3 and Month 6 of treatment, as well as at the final visit of the follow -up period or early  
termination visit in order to assess for any signs  of pre-existing or treatment -emergent neurological abnormalities such as stroke or other cerebrovascular 
events .
eElectrocardiograms ( ECG s)will be performed at Visit 1, Visit 3, Visit 12, and Visit 1 4or early termination.  Note :  The Visit 3 ECG shou ld be collected prior 
to blood draws and dosing.  Patients must be supine for approximately 5 to 10 minutes before ECG collection and remain supine but awake during ECG 
collection .
fVital signs will include b ody temperature, blood pressure and pulse.  Blood pressure and pulse will be measured in triplicate in the sitting position and should 
be measured prior to blood draws.  Blood pressure will be assessed by utilizing a calibrated machine .
gChemistry samples collected at Visit 3 , Visit 7, Visit 12, and Visit 14 or early termination must be fasting. Fasting is defined as no food or drink, except 
water, for at least 8 hours prior to testing .
hIn the event of a positive urine leukocyte esterase result, a repeat urine sample will be collecte dand shipped to the central laboratory .
iA positive urine test must be followed by a serum pregnancy test for confirmation.
jImmunogenicity,  and PK sampling to be performed at the indicated visits and prior to dose administration if the visit is a dosing visit.  
Samples will be taken in the event of early termination .  Immunogenicity samples also may be collected in the event of a systemic allergic/hypersensitivity 
reaction (see Section 8.4.3).  The timing of samples will be recorded.
kPatients will receive injections of placebo or LY2951742 after all other visit procedures are completed.  Following the first dose at Visit 3, patients will be 
observed for at least 30 minutes in the office.
lQuestionnaire administered by clinician to assess other chronic pain conditions .
mThe C -SSRS and SHSF (and SHFU when applicable) will be completed at scheduled and unscheduled office visits.
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 63
LY2951742 Approved: 22 January 2016Appendix 3. Clinical Laboratory  Tests
Hematology : Clinical Chemistryb:
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocy tes Aspartate aminotransferase (AST)
Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acid
Platelets
HbA 1cCalcium
Glucose (fasting )b
Albumin
Creatine kinase (CK)
Triglycerides
Total cholesterolb
HDLb
Urinalysis :
Specific gravity
pH
Insulin (fasting)b
C-peptide (fasting)b
Protein
Glucose
Ketones
Blood
Urine leukocyte esterasea
Microscopic analysisa
Urine cultureaOther
PK Sample (LY2951742 serum concentration 
determination)
Immunogenicity
Urine Drug Screenc
Pregnancy Test (females only)c 
Serum pregnancy or FSH
Urine pregnancy test (local)
Stored Samples
Biomarker storage
RNA
Abbreviations:  FSH = follicle -stimulating hormone; HDL = high density lipoprotein;
PK = pharmacokinetic; RBC = red blood cells; RNA = ribonucleic acid; WBC = white blood cells.
CCI
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 64
LY2951742 Approved: 22 January 2016Clinical Laboratory Tests (footnotes)
aA positive urine leukocyte esterase result will require a follow -up sample with microscopic analysis and possibly 
a urine culture.
bFasting laboratory samples will be collected as shown in the Schedule of Activities (Appendix 2 ).  Fasting is 
defined as no food or drink, except water, for at least 8 hours prior to testing.  All other samples may be collected 
on a no nfasting basis.
cMay be repeated during the study at the discretion of the investigator.
I5Q-MC-CGAH (a)Clinical Protocol Page 65
LY2951742 Approved: 22 January 2016Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnor mality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with the Lilly , or i ts desi gnee, clinical 
research physician.
Hepatic Monitoring Tests
Hepatic Hem atology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT
CPKAlkaline phosphatase isoenzymes a
Anti -Actin antibody a
Anti -smooth muscle antibody a
Abbreviations:  ALT = alanine aminotransferase; AST = aspirate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normali zed 
ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
I5Q-MC-CGAH (a)Clinical Protocol Page 66
LY2951742 Approved: 22 January 2016Appendix 5. Protocol A mendment I5Q -MC-CGAH(a) 
Summary :  A Phase 3, Randomized, Double -Blind, 
Placebo- Controlled Study  of LY2951742 in Patients with 
Episodic Migraine –the EVOLVE -2 Study  
Overview
Protocol  I5Q-MC-CGAH (CGAH ) [A Phase 3 , Rando mized, Double -Blind, Pl acebo -Controlled 
Study  of LY2951742 i n Pat ients with Episodi c Migraine – the EVOLVE -2 Study ] has been 
amended.  The new protoc ol is indicated by  amendment ( a) and will be used to conduct the study 
in place of any  preceding ver sion of the protocol .
The changes were requi red by 4 European Union Member States participating in the Vo luntary 
Harm onisat ion Procedure.  The key  changes are as fo llows:
Added the protocol amendment approval date (with updated trial alias) on every  
page o f the protocol.
Added language regarding the contents of each injection for the different 
treatm ent assi gnments in order to clarify how treatment is blinded (Secti on 4.1).
Excluded patients with a prior lifet ime history  of stroke (Secti on 5.2, Exclusio n 
[23]) to provi de addi tional safeguards for pati ents who may  be at ri sk for stroke.
Added text to indicate that neurological examinat ions will be conducted to assess 
for possible cerebrovascular events, along with instructions for appropriate 
follow-up (Secti on 8.4.5, Safety  Moni toring).
Revised wording regarding procedures associated with emergency  unblinding
(Secti on 6.3) such that i nvest igators no longer need to contact Lilly prior to 
emergency unblinding of a pati ent’s treatm ent assignment.
Added thelist of allowed and disallowed conco mitant treatm ents di rectly into 
Secti on 6.8 rather than referencing a separate document .
Modified treatment discont inuat ion criteria (Secti on 7.1.1) to requi re(rather than
recommend )discontinuati on of  treatm ent in the event of specific liver function 
test abnorm alities, and a dded language to indicate the additional events requiring 
discontinuat ion fromLY2951742 or pl acebo .
Added informat ion regarding the approximate number of countries, invest igative 
sites, and pat ients planned for inclusio n in Study  CGAH (Secti on 9.1).
Added clarificat ion on the statistical model to be used for subgroup analyses 
(Secti on 9.7.2) .
Provi ded l anguage clarifying the timing, and intent, of planned interim analyses 
(Secti on 9.8).
Updated the Schedule of Activit ies and footnotes to reflect added neurological 
examinat ions.
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 67
LY2951742 Approved: 22 January 2016Revised Protocol Sect ions
Header
I5Q-MC-CGAH (a)Clinical Protocol
Footer
Approved: XX January 2016
Title
Protocol I5Q-MC-CGA H(a)
4. Study  Design
4.1 Overview of Study Design
Patients randomized to the 120 mg dose of LY2951742 will receive an init ial loading dose of 
240 m g (2 inject ions of 120 m g each at Vi sit 3 only).  To preserve blinding throughout the study , 
patients in all treatm ent groups will receive 2 injections of inve stigational product at each dosing 
visit (two pl acebo inject ions, two 120 -mg LY2951742 injections, or one placebo inject ion and 
one 120 -mg inject ion).  At Visit 3, if available and where local regulations and Ethical Review 
Boards allow, patients will also watch a training video designed to address patient expectations 
with regard to parti cipat ion in a placebo -controlled trial and the difference between medical 
treatm ent and research.
Patients will  be given inject ions of invest igational product during offic e visits (Figure CGAH.1) .  
For all treatment groups, subcutaneous inject ionswill be administered once monthly at the 
dosing visits.  A t Visi t 3(first dose) , pati ents will be requi red to rem ain in the office for 
observat ionfor 30 minutes post inject ion.  Pati ents will cont inue to log in and com plete the 
ePRO diary each day .  Pati ents m ay cont inue to take thei r allowed acute migraine headache 
medicat ion(with som e limi tations; see Secti on6.8concomitant medicat ion study  tool) during 
the treatment phase.
Study Period IV :  During this 4- month phase, si tes and pat ients will remain blinded to patients’ 
treatm ent assi gnments.  Pati ents will  follow all study  procedures during Study  Period IV but will 
not receive LY2951742 or placebo. One month after Visit 12, if clinically warranted due to a 
worsenin g of symptom s, patients may  start mi graine preventi on medicat ions at the discretion of 
the invest igator.  The list of allowed prevent ive medications is provided in Secti on6.8the 
concomitant medicat ions study  tool.  At Visi t 14 (Month 10), pati ents will return to the site for 
their last study  visit and di scharge from  the study .
I5Q-MC-CGAH (a)Clinical Protocol Page 68
LY2951742 Approved: 22 January 20165.2 Exclusion Criteria
Medical Conditions
[23] Have ECGs showing abnorm alities com patible wit h acute cardiovascular 
events and/or serious cardiovascular risk, including but not limited to a 
corrected QT (QTcB [Bazett's] ) interval > 470 m sec for wom en and >450 for 
men, or have had my ocardial  infarcti on, unstable angina, percutaneous 
coronary  intervent ion, coronary  artery  bypass graft, stroke, or deep vein 
thrombosis/pulmo nary embo lism wit hin 6 months of screening, or have 
planned cardio vascular surgery or percutaneous coronary  angi oplasty , or 
patients wi th a lifet ime history of stroke .
5.3 Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be
considered for rescreen once, wi th approval  from Lilly Medical  for only  the cri teria shown 
below.  The interval between screening and rescreening mustbe at l east 45 days or longer if 
requi red for the specified timeframes in the inclusion/exclusion criteria or concomitant 
medicat ions requi rements study  tool.  If rescreening is performed, the individual must si gn a new 
ICF andwill be assigned a new i dentificat ion number.
6.3 Blinding
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a pati ent’s treatm ent assignment is warranted. Patient safet y must always be the first 
consideration in making such a determinat ion.If the invest igator decides that unblinding is 
warranted, the invest igator should make every effo rt to con tact the Lilly CRP/CRS prior to 
unblinding a patient’s treatment assignment. If an emergency unblinding occurs, a pati ent’s 
treatm ent assi gnment i s unblinded, Lilly  must be notified as soon as possible immediately .
I5Q-MC-CGAH (a)Clinical Protocol Page 69
LY2951742 Approved: 22 January 20166.8 Concomitant Therapy
Table CGAH.3 contains a list of medicat ions that are, and are not, allowed in this study.  Note 
that acute treatment of migraine headache is allowed throughout the study but with so me 
limitations.  Treatments used for the prevent ion of migraine are not allowed at any  time during 
Study  Periods I through III.
Table CGAH.3. Treatments Allowed and Treatments Not Allowed as Concomitant 
Therapy
Medications allowed for the ACUTE treatment of migraine headaches or other pain or 
injury:
Acetaminophen (paracetamol), NSAIDs; Triptans; Ergotamine and derivatives; Isometheptene mucate, 
dichloralphenazone and acetaminophen combination (Midrin); or combinations thereof.
The following medications are allowed with restrictions:
3.Opioid and barbiturates no more than 3 days/month (SP II, III and IV).
4.Single dose of injectable steroids allowed only once during the study, in an emergency setti ng (SP III and IV).
Medications, Procedures or Devices not allowed for any reason/indication:
Acetazolamide
Acupuncture
Anticonvulsants/Antiepileptics
Antipsychotics
Beta-blockers
Botulinum toxin applied to head/neck area
Cannabis / Cannabinoids
Chiropractic procedures, physiotherapy, TENS or other electric devices on head and neck
Corticosteroids for oral use
Flunarizine
Herbals with anti -inflammatory effect (feverfew, willow bark, petasites/butterbur), herbals with sympathomimetic 
effect (ma hua ng, ephedra, bitter orange, synephrine) and herbals with catecholamine transmitter reuptake 
inhibition (St John’s Wort)
Monoamine oxidase inhibitors (MAOIs)
Memantine
Serotonin 5HT2a/2c antagonists, ege.g.:  trazodone, nefazodone
Stimulants (prescription s trength), ege.g.:  methylphenidate, dextroamphetamine, mixed amphetamine salts
Tizanidine
Therapeutic antibodies, ege.g.:  adalimumab, infliximab, trastuzumab, bevacizumab, etanercept, etc.
Tricyclic antidepressants (TCAs)
Triptans for prophylaxis of menst rual related migraine
Venlafaxine
Verapamil
Restricted medication during SP II -III:  Use of the following medications for indications 
other than migraine prevention is allowed providing the dose is stable 2 months prior to 
Visit 2 and is expected to remai n stable during Visit 2 through -V12.
ACE inhibitors
Angiotensin receptor blockers (ARBs)
Benzodiazepines
I5Q-MC-CGAH (a)Clinical Protocol Page 70
LY2951742 Approved: 22 January 2016Bupropion 
Calcium -channel blockers (except verapamil and flunarizine)
Clonidine
Guanfacine
Mirtazapine
SSRIs/NRIs/SNRIs (other than venlafaxine)
Use of electric devices (i.e. TENS), physiotherapy, chiropractic procedures on low back and extremities
Restricted medication during SP II -III:  Use of the following medications for indications 
other than migraine prevention is allowed:
Beta-blockers, ophthal mic
Cyclandelate
Cyproheptadine
Melatonin
SP IV (After Visit 12)
One month after Visit 12, if clinically warranted due to a worsening of symptoms, patients may start migraine 
prevention medications at the discretion of the investigator with the exception of antipsychotics, cannabis and 
cannabinoids, MAOIs, memantine, serotonin 5HT2a/2c antagonists, and stimulants, which remain excluded .
The list of medicat ions allowed or not allowed for the acute treatment of migraine, as well as 
those prohibited for the prevent ion of migraine, is provided in the concomitant medicat ion list in 
the concomitant medications study  tool, along wi th all  concomi tant therapies allo wed or not 
allowed during the study .  Note that there are some limitat ions regarding conco mitant 
medications for the acute treatment of migraines during the study .  Any  changes in the list of 
allowed/not allowed medications will be communicated to invest igators and will not constitute a 
protocol  amendment. 
7. Discontinuation Criteria
7.1 Discontinuation from Study Treatment
7.1.1. Permanent Discontinuation from Study Treatment
Discontinuati on of  the invest igational product is required in cases of pregnancy.
Discontinuati on of  the invest igational product for abnormal liver tests is required should be 
considered by the investigator when a patient meets one of the fo llowing condi tions and the 
event i s at l east possibly  related to study  drug after consul tation wi th the Lilly designated medical 
monitor:
ALT or aspartate aminotransferase (AST) >8X ULN
ALT or AST >5X ULN for more than 2 weeks
ALT or AST >3X ULN and TBL >2X ULN or prothrombin t ime >1.5X ULN
I5Q-MC-CGAH (a)Clinical Protocol Page 71
LY2951742 Approved: 22 January 2016ALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5 %)
ALP >3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.5XULN with the appearance of fatigue, nausea, vo miting, right quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%)
Discontinuati on of  investigat ional product also is required in the fo llowing cases, if the event is 
at least possibly related to study  drug:
Serious allergi c react ion to study  drug
Serious injection -site reacti on
Serious event of suicidalit y or depressi on
Serious cerebrovascular event.
8. Study  Assessments and Procedures
8.4 Safety Assessments
8.4.5 Safety Monitoring
Neurol ogical examinat ions will be conducted at screening, Month 3 and Month 6 of treatment, as 
well as at the final visit of the fo llow-up peri od or early  terminat ion visit in order to assess for 
any signs o f pre-existing or treatment -emergent neurol ogical  abnorm alities such as stroke or 
other cerebrovascular events.  If a study  patient experiences signs of a cerebrovascular event, 
appropriate fo llow-up and clinical management should be conducted by  the investi gator , and the 
Lilly CRP/CRS should be consulted regarding co llection of further clinical informat ion and 
follow-up testing.
9. Statistical Considerations and Data A nalysis
9.1 Determination of Sample Size
Approximately  100 si tes in 11 countri es are pl anned for inclusio n in Study CGAH, with an 
average o f approximately  8 pati ents to be randomized at each invest igative site.  The final 
number of sites, countries, and patients per site may vary depending on sites’ enro llment rates.
9.2 General Statistical Consid erations
The primary  analys is will be performed using a restricted maximum likelihood -based mixed 
models repeated m easures (MMRM) technique with prespecified m odel terms (Secti on9.4.1 ).
I5Q-MC-CGAH (a)Clinical Protocol Page 72
LY2951742 Approved: 22 January 2016Any change to the data analysis methods described in the protocol wi ll requi re an amendment 
ONLY if it changes a principal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the clinical study  report or SAP .  Changes may only be made in the SAP prior to unblinding.  
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.
9.4 Primary  and Secondar y Anal yses
9.4.2. Key Secondary Analyses
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 73
LY2951742 Approved: 22 January 2016There will be no adjust ments for m ultiplicity for analyses of other endpoints.  If the mult iple 
testing approach for key  secondary  measures only  needs to be changed, the updated approach 
will be provided in the SAP, and it should not lead to modification of this protocol.
9.7.2 Subgroup Analyses
Subgroup analyses will be performed for the primary efficacy measure (change fro m baseline in 
the number of migraine headache days) separately  foreach of the subgroup populat ions listed in
Table CGAH.4.   Subgroup analyses will be conducte d only for the ITT patients in Study  Period 
III.
Each of t The subgroup analyses for the primary measure of change fro m baseline in the number 
of migraine headache days will be conducted using MMRM.  The same MMRM model 
described in Section 9.4.1 will be used, wi th term s of subgroup, subgroup -by-treatm ent, 
subgroup -by-month, and subgroup -by-treatm ent-by-month interacti ons added as addit ional 
covari ates.
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 74
LY2951742 Approved: 22 January 2016Table CGAH. 34. Definition of Subgroup Variables
9.8 Interim Analyses
Two interim analyses are anticipated for this study.  The first possible interim analysis will occur 
during Study  Period III (doubl e-blind treatment) and could result in stopping the trial for safety 
or fut ility.  Details will be documented in the Statisti cal Analysis Center SAP and the DMC 
Charter.  A DMC will be convened to assess safet y and fut ility analyses.  This analysis is 
planned to occur when approximately 330 (40% of the total sample size) randomized pat ients 
have had the chance to complete at lea st 3 m onths of the treatment period.  The interim analysis 
will be conducted by an independent data monitoring co mmit tee (DMC) wi th members external 
to Lilly .  The data from  the interim  analysis will  be used to evaluate whether to stop or modify 
the study  for futility and/or safet y issues.  Stopping rules for futilit y at thi s interim analysis will 
be based on the condit ional power of comparing LY2951742 to placebo.  Specifically, 
condi tional power represents the probabilit y that the ongoing tri al will resul t in a statist ically 
significant difference between LY2951742 and placebo at end of the trial, based on the data 
available at the time of the interim analysis.  Rules for stopping the study  are detailed in the 
Statistical Analysis Center SAP and the DMC Ch arter.   Only the DMC is authorized to evaluate 
unblinded interim efficacy and safet y analyses.   Study  sites will  receive informat ion about 
interim results ONLY if they need to know for the safet y of their pati ents.  There is no inflat ion 
of type 1 error du e to the conduct of a futilit y analysis (Snapinn et al. 2006), so no adjustment to 
the nominal significance level will be made for the primary analysis as a result of a futilit y 
assessment.
CCI
I5Q-MC-CGAH (a)Clinical Protocol Page 75
LY2951742 Approved: 22 January 2016Appendix 2Schedule of A ctivities
Schedule of Activities , Protocol I5Q-MC-CGAH
Study Period (SP)SP I-
ScreeningSP II -
Prospective 
BaselineSP III -Treatment SP IV –Follow -up
(Target) I nterval (days) 
since previous visit30-45 14 16 30 30 30 15 15 15 15 60 60
ETAllowable range (days) 
between visits3-45 30-40a
Interval allowance (days) +/- 1 +/- 3 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 5 +/- 5
Visit 1 2 3 4 b 5 6 7 8 9c10 11c12 13 14
Month 0 0.5 1 2 3 4 4.5 5 5.5 6 8 10
Assessments and Procedures
Physical examination d X
Neurological 
examination d X X X X X
Schedule of Activities , Protocol I5Q-MC-CGAH (footnotes)
dPhysical examinations at screening must include a neurological exam. A neurological exam will be conducted at screening, Month 3 and Month 6 of treatment, 
as well as at the final visit of the follow -up period or early  termination visit in order to assess for any signs of pre -existing or treatment -emergent neurological 
abnorma lities such as stroke or other cerebrovascular events.
Leo Document ID = 0141c58f-0217-46f5-9eb1-151a7b7010e3
Approver: 
Approval Date & Time: 22-Jan-2016 16:59:38 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 22-Jan-2016 20:45:52 GMT
Signature meaning: Approved
PPD
PPD